

Shared Genetic Risk between Eating Disorder- and Substance-Use-Related Phenotypes: Evidence from Genome-Wide Association Studies

Melissa A. Munn-Chernoff¹, Emma C. Johnson², Yi-Ling Chou², Jonathan R.I. Coleman^{3,4}, Laura M. Thornton¹, Raymond K. Walters^{5,6}, Zeynep Yilmaz^{1,7}, Jessica H. Baker¹, Christopher Hübel^{3,8}, Scott Gordon⁹, Sarah E. Medland⁹, Hunna J. Watson^{1,10,11}, Héléna A. Gaspar^{3,4}, Julien Bryois⁸, Anke Hinney¹², Virpi M. Leppä⁸, Manuel Mattheisen^{13,14,15,16}, Stephan Ripke^{5,6,17}, Shuyang Yao⁸, Paola Giusti-Rodríguez⁷, Ken B. Hanscombe¹⁸, Roger A.H. Adan^{19,20,21}, Lars Alfredsson²², Tetsuya Ando²³, Ole A. Andreassen²⁴, Wade H. Berrettini²⁵, Ilka Boehm²⁶, Claudette Boni²⁷, Vesna Boraska Perica^{28,29}, Katharina Buehren³⁰, Roland Burghardt³¹, Matteo Cassina³², Sven Cichon^{33,34,35}, Maurizio Clementi³², Roger D. Cone³⁶, Philippe Courtet³⁷, Scott Crow³⁸, James J. Crowley^{7,14}, Unna N. Danner³⁹, Oliver S.P. Davis^{40,41}, Martina de Zwaan⁴², George Dedoussis⁴³, Daniela Degortes⁴⁴, Janiece E. DeSocio⁴⁵, Danielle M. Dick^{46,47,48}, Dimitris Dikeos⁴⁹, Christian Dina⁵⁰, Monika Dmitrzak-Weglarz⁵¹, Elisa Docampo^{52,53,54}, Laramie E. Duncan⁵⁵, Karin Egberts⁵⁶, Stefan Ehrlich²⁶, Geòrgia Escaramís^{52,53,54}, Tõnu Esko^{57,58}, Xavier Estivill^{52,53,54,59}, Anne Farmer³, Angela Favaro⁴⁴, Fernando Fernández-Aranda^{60,61}, Manfred M. Fichter^{62,63}, Krista Fischer⁵⁷, Manuel Föcker⁶⁴, Lenka Foretova⁶⁵, Andreas J. Forstner^{34,66,67,68}, Monica Forzan³², Christopher S. Franklin²⁸, Steven Gallinger⁶⁹, Ina Giegling⁷⁰, Johanna Giuranna⁷¹, Fragiskos Gonidakis⁷², Philip Gorwood^{73,74}, Monica Gratacos Mayora^{52,53,54}, Sébastien Guillaume³⁷, Yiran Guo⁷⁵, Hakon Hakonarson^{75,76}, Konstantinos Hatzikotoulas^{28,77}, Joanna Hauser⁷⁸, Johannes Hebebrand¹², Sietske G. Helder^{3,79}, Stefan Herms^{33,34}, Beate Herpertz-Dahlmann³⁰, Wolfgang Herzog⁸⁰, Laura M. Huckins^{28,81}, James I. Hudson⁸², Hartmut Imgart⁸³, Hidetoshi Inoko⁸⁴, Vladimir Janout⁸⁵, Susana Jiménez-Murcia^{60,61}, Antonio Julià⁸⁶, Gursharan Kalsi³, Deborah Kaminská⁸⁷, Leila Karhunen⁸⁸, Andreas Karwautz⁸⁹, Martien J.H. Kas^{19,90}, James L. Kennedy^{91,92,93}, Anna Keski-Rahkonen⁹⁴, Kirsty Kiezebrink⁹⁵, Youl-Ri Kim⁹⁶, Kelly L. Klump⁹⁷, Gun Peggy S. Knudsen⁹⁸, Maria C. La Via¹, Stephanie Le Hellard^{99,100,101}, Robert D. Levitan⁹², Dong Li⁷⁵, Lisa Lilienfeld¹⁰², Bochao Danae Lin¹⁹, Jolanta Lissowska¹⁰³, Jurjen Luykx¹⁹, Pierre J. Magistretti^{104,105}, Mario Maj¹⁰⁶, Katrin Mannik^{57,107}, Sara Marsal⁸⁶, Christian R. Marshall¹⁰⁸, Morten Mattingsdal¹⁰⁹, Sara McDevitt^{110,111}, Peter McGuffin³, Andres Metspalu^{57,112}, Ingrid Meulenbelt¹¹³, Nadia Micali^{114,115}, Karen Mitchell^{116,117}, Alessio Maria Monteleone¹⁰⁶, Palmiero Monteleone¹¹⁸, Benedetta Nacmias¹¹⁹, Marie Navratilova⁶⁵, Ioanna Ntalla⁴³, Julie K. O'Toole¹²⁰, Roel A. Ophoff^{121,122}, Leonid Padyukov¹²³, Aarno Palotie^{58,124,125}, Jacques Pantel²⁷, Hana Papezova⁸⁷, Dalila Pinto⁸¹, Raquel Rabionet^{126,127,128}, Anu Raevuori⁹⁴, Nicolas Ramoz²⁷, Ted Reichborn-Kjennerud^{98,129}, Valdo Ricca¹³⁰, Samuli Ripatti¹³¹, Franziska Ritschel^{26,132}, Marion Roberts³, Alessandro Rotondo¹³³, Dan Rujescu⁷⁰, Filip Rybakowski¹³⁴, Paolo Santonastaso¹³⁵, André Scherag¹³⁶, Stephen W. Scherer^{137,138}, Ulrike Schmidt¹³⁹, Nicholas J. Schork¹⁴⁰, Alexandra Schosser¹⁴¹, Jochen Seitz³⁰, Lenka Slachtova¹⁴², P. Eline Slagboom¹⁴³, Margarita C.T. Slof-Op 't Landt^{144,145}, Agnieszka Slopian¹⁴⁶, Sandro Sorbi^{119,147}, Beata Świątkowska¹⁴⁸, Jin P. Szatkiewicz⁷, Ioanna Tachmazidou²⁸, Elena Tenconi⁴⁴, Alfonso Tortorella^{149,150}, Federica Tozzi¹⁵¹, Janet Treasure¹³⁹, Artemis Tsitsika¹⁵², Marta Tyszkiewicz-Nwafor¹⁴⁶, Konstantinos Tziouvas¹⁵³, Annemarie A. van Elburg^{20,154}, Eric F. van Furth^{144,145}, Gudrun Wagner⁸⁹, Esther Walton²⁶, Elisabeth Widen¹²⁴, Eleftheria Zeggini^{28,77}, Stephanie Zerwas¹, Stephan Zipfel¹⁵⁵, Andrew W. Bergen^{156,157}, Joseph M. Boden¹⁵⁸, Harry Brandt¹⁵⁹,

Steven Crawford¹⁵⁹, Katherine A. Halmi¹⁶⁰, L. John Horwood¹⁵⁸, Craig Johnson¹⁶¹, Allan S. Kaplan^{91,92,93}, Walter H. Kaye¹⁶², James Mitchell¹⁶³, Catherine M. Olsen¹⁶⁴, John F. Pearson¹⁶⁵, Nancy L. Pedersen⁸, Michael Strober^{166,167}, Thomas Werge¹⁶⁸, David C. Whiteman¹⁶⁴, D. Blake Woodside^{92,93,169,170}, Jakob Grove^{13,171,172,173}, Anjali K. Henders¹⁷⁴, Janne T. Larsen^{171,175,176}, Richard Parker⁹, Liselotte V. Petersen^{171,175,176}, Jennifer Jordan^{177,178}, Martin A. Kennedy¹⁷⁹, Andreas Birgegård^{8,14,15}, Paul Lichtenstein⁸, Claes Norring^{14,15}, Mikael Landén^{8,180}, Preben Bo Mortensen^{171,175,176}, Renato Polimanti^{181,182}, Jeanette N. McClintick¹⁸³, Amy E. Adkins^{46,47}, Fazil Aliev⁴⁶, Silviu-Alin Bacanu^{184,185,186}, Anthony Batzler¹⁸⁷, Sarah Bertelsen¹⁸⁸, Joanna M. Biernacka^{189,190}, Tim B. Bigdeli¹⁹¹, Li-Shiun Chen², Toni-Kim Clarke¹⁹², Franziska Degenhardt¹⁹³, Anna R. Docherty¹⁹⁴, Alexis C. Edwards^{185,186}, Jerome C. Foo¹⁹⁵, Louis Fox², Josef Frank¹⁹⁵, Laura M. Hack⁵⁵, Annette M. Hartmann⁷⁰, Sarah M. Hartz², Stefanie Heilmann-Heimbach¹⁹³, Colin Hodgkinson¹⁹⁶, Per Hoffmann^{197,198,199}, Jouke-Jan Hottenga²⁰⁰, Bettina Konte⁷⁰, Jari Lahti²⁰¹, Marius Lahti-Pulkkinen²⁰², Dongbing Lai²⁰³, Lannie Ligthart²⁰⁰, Anu Loukola¹²⁴, Brion S. Maher²⁰⁴, Hamdi Mbarek²⁰⁰, Andrew M. McIntosh²⁰⁵, Matthew B. McQueen²⁰⁶, Jacquelyn L. Meyers²⁰⁷, Yuri Milaneschi²⁰⁸, Teemu Palviainen¹²⁴, Roseann E. Peterson^{185,186}, Euijung Ryu¹⁸⁹, Nancy L. Saccone²⁰⁹, Jessica E. Salvatore^{46,185,186}, Sandra Sanchez-Roige¹⁶², Melanie Schwandt²¹⁰, Richard Sherva²¹¹, Fabian Streit¹⁹⁵, Jana Strohmaier¹⁹⁵, Nathaniel Thomas^{46,47}, Jen-Chyong Wang¹⁸⁸, Bradley T. Webb^{184,185,186}, Robbee Wedow^{5,6,212,213}, Leah Wetherill²⁰³, Amanda G. Wills²¹⁴, Hang Zhou^{181,182}, Jason D. Boardman^{215,216}, Danfeng Chen⁶, Doo-Sup Choi²¹⁷, William E. Copeland²¹⁸, Robert C. Culverhouse²¹⁹, Norbert Dahmen²²⁰, Louisa Degenhardt²²¹, Benjamin W. Domingue²²², Mark A. Frye¹⁹⁰, Wolfgang Gäbel²²³, Caroline Hayward²²⁴, Marcus Ising²²⁵, Margaret Keyes²²⁶, Falk Kiefer²²⁷, Gabrielle Koller²²⁸, John Kramer²²⁹, Samuel Kuperman²²⁹, Susanne Lucae²²⁵, Michael T. Lynskey²³⁰, Wolfgang Maier²³¹, Karl Mann²²⁷, Satu Männistö²³², Bertram Müller-Myhsok²³³, Alison D. Murray²³⁴, John I. Nurnberger^{203,235}, Ulrich Preuss^{236,237}, Katri Räikkönen²⁰², Maureen D. Reynolds²³⁸, Monika Ridinger²³⁹, Norbert Scherbaum^{240,241,242}, Marc A. Schuckit¹⁶², Michael Soyka^{243,244}, Jens Treutlein¹⁹⁵, Stephanie H. Witt¹⁹⁵, Norbert Wodarz²⁴⁵, Peter Zill²⁴⁶, Daniel E. Adkins^{194,247}, Dorret I. Boomsma²⁰⁰, Laura J. Bierut², Sandra A. Brown^{162,248}, Kathleen K. Bucholz², E. Jane Costello²⁴⁹, Harriet de Wit²⁵⁰, Nancy Diazgranados²⁵¹, Johan G. Eriksson^{252,253}, Lindsay A. Farrer^{211,254,255,256,257}, Tatiana M. Foroud²⁰³, Nathan A. Gillespie^{185,186}, Alison M. Goate¹⁸⁸, David Goldman^{196,258}, Richard A. Grucza², Dana B. Hancock²⁵⁹, Kathleen Mullan Harris^{260,261}, Victor Hesselbrock²⁶², John K. Hewitt²⁶³, Christian J. Hopfer²⁶⁴, William G. Iacono²²⁶, Eric O. Johnson^{259,265}, Victor M. Karpyak¹⁹⁰, Kenneth S. Kendler^{185,186}, Henry R. Kranzler^{266,267}, Kenneth Krauter²⁶⁸, Penelope A. Lind⁹, Matt McGue²²⁶, James MacKillop^{269,270}, Pamela A.F. Madden², Hermine H. Maes¹⁸⁵, Patrik K.E. Magnusson⁸, Elliot C. Nelson², Markus M. Nöthen¹⁹³, Abraham A. Palmer^{162,271}, Brenda W.J.H. Penninx²⁷², Bernice Porjesz²⁰⁷, John P. Rice², Marcella Rietschel¹⁹⁵, Brien P. Riley^{184,185,186}, Richard J. Rose²⁷³, Pei-Hong Shen¹⁹⁶, Judy Silberg^{185,186}, Michael C. Stallings²⁶³, Ralph E. Tarter²⁷⁴, Michael M. Vanyukov²⁷⁴, Scott Vrieze²²⁶, Tamara L. Wall¹⁶², John B. Whitfield⁹, Hongyu Zhao²⁷⁵, Benjamin M. Neale^{5,6}, Tracey D. Wade²⁷⁶, Andrew C. Heath², Grant W. Montgomery^{9,174,277}, Nicholas G. Martin⁹, Patrick F. Sullivan^{1,7,8}, Jaakko Kaprio^{94,124}, Gerome Breen^{3,4}, Joel Gelernter^{181,182,278,279}, Howard J. Edenberg^{183,203}, Cynthia M. Bulik^{1,8,280*}, Arpana Agrawal^{2*}

¹Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA, ²Department of Psychiatry, Washington University School of Medicine, Saint Louis, Missouri, USA, ³Institute of Psychiatry, Psychology and Neuroscience, Social, Genetic and Developmental Psychiatry (SGDP) Centre, King's College London, London, UK, ⁴National Institute for Health Research Biomedical Research Centre, King's College London and South London and Maudsley National Health Service Trust, London, UK, ⁵Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA, ⁶Stanley Center for Psychiatric Research, Broad Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, USA, ⁷Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA, ⁸Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden, ⁹QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia, ¹⁰School of Psychology, Curtin University, Perth, Western Australia, Australia, ¹¹School of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia, ¹²Department of Child and Adolescent Psychiatry, University Hospital Essen, University of Duisburg-Essen, Essen, Germany, ¹³Department of Biomedicine, Aarhus University, Aarhus, Denmark, ¹⁴Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, ¹⁵Center for Psychiatry Research, Stockholm Health Care Services, Stockholm City Council, Stockholm, Sweden, ¹⁶Department of Psychiatry, Psychosomatics and Psychotherapy, University of Würzburg, Würzburg, Germany, ¹⁷Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin, Berlin, Germany, ¹⁸Department of Medical and Molecular Genetics, King's College London, Guy's Hospital, London, UK, ¹⁹Brain Center Rudolf Magnus, Department of Translational Neuroscience, University Medical Center Utrecht, Utrecht, The Netherlands, ²⁰Center for Eating Disorders Rintveld, Altrecht Mental Health Institute, Zeist, The Netherlands, ²¹Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ²²Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ²³Department of Behavioral Medicine, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan, ²⁴NORMENT Centre, Division of Mental Health and Addiction, University of Oslo, Oslo University Hospital, Oslo, Norway, ²⁵Department of Psychiatry, Center for Neurobiology and Behavior, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA, ²⁶Division of Psychological and Social Medicine and Developmental Neurosciences, Faculty of Medicine, Technische Universität Dresden, Dresden, Germany, ²⁷INSERM U894, Centre of Psychiatry and Neuroscience, Paris, France, ²⁸Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK, ²⁹Department of Medical Biology, School of Medicine, University of Split, Split, Croatia, ³⁰Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, RWTH Aachen University, Aachen, Germany, ³¹Klinikum Frankfurt/Oder, Frankfurt, Germany, ³²Clinical Genetics Unit, Department of Woman and Child Health, University of Padova, Padova, Italy, ³³Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland, ³⁴Department of Biomedicine, University of Basel, Basel, Switzerland, ³⁵Institute of Neuroscience and Medicine (INM-1), Research Center Juelich, Juelich, Germany, ³⁶Life Sciences Institute and Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan, USA, ³⁷Department of Emergency

Psychiatry and Post-Acute Care, CHRU Montpellier, University of Montpellier, Montpellier, France, ³⁸Department of Psychiatry, University of Minnesota, Minneapolis, Minnesota, USA, ³⁹Altrecht Eating Disorders Rintveld, Altrecht Mental Health Institute, Zeist, The Netherlands, ⁴⁰MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK, ⁴¹School of Social and Community Medicine, University of Bristol, Bristol, UK, ⁴²Department of Psychosomatic Medicine and Psychotherapy, Hannover Medical School, Hannover, Germany, ⁴³Department of Nutrition and Dietetics, Harokopio University, Athens, Greece, ⁴⁴Department of Neurosciences, University of Padova, Padova, Italy, ⁴⁵College of Nursing, Seattle University, Seattle, Washington, USA, ⁴⁶Department of Psychology, Virginia Commonwealth University, Richmond, Virginia, USA, ⁴⁷College Behavioral and Emotional Health Institute, Virginia Commonwealth University, Richmond, Virginia, USA, ⁴⁸Department of Human & Molecular Genetics, Virginia Commonwealth University, Richmond, Virginia, USA, ⁴⁹Department of Psychiatry, Athens University Medical School, Athens University, Athens, Greece, ⁵⁰l'institut du thorax, INSERM, CNRS, Univ Nantes, Nantes, France, ⁵¹Department of Psychiatric Genetics, Poznan University of Medical Sciences, Poznan, Poland, ⁵²Barcelona Institute of Science and Technology, Barcelona, Spain, ⁵³Universitat Pompeu Fabra, Barcelona, Spain, ⁵⁴Centro de Investigación Biomédica en Red en Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, ⁵⁵Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California, USA, ⁵⁶Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Würzburg, Centre for Mental Health, Würzburg, Germany, ⁵⁷Estonian Genome Center, University of Tartu, Tartu, Estonia, ⁵⁸Program in Medical and Population Genetics, Broad Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, USA, ⁵⁹Genomics and Disease, Bioinformatics and Genomics Programme, Centre for Genomic Regulation, Barcelona, Spain, ⁶⁰Department of Psychiatry, University Hospital of Bellvitge –IDIBELL and CIBERobn, Barcelona, Spain, ⁶¹Department of Clinical Sciences, School of Medicine, University of Barcelona, Barcelona, Spain, ⁶²Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, Munich, Germany, ⁶³Schön Klinik Roseneck affiliated with the Medical Faculty of the University of Munich, Munich, Germany, ⁶⁴Department of Child and Adolescent Psychiatry, University of Münster, Münster, Germany, ⁶⁵Department of Cancer, Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic, ⁶⁶Centre for Human Genetics, University of Marburg, Marburg, Germany, ⁶⁷Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, Germany, ⁶⁸Department of Psychiatry (UPK), University of Basel, Basel, Switzerland, ⁶⁹Department of Surgery, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada, ⁷⁰Department of Psychiatry, Psychotherapy and Psychosomatics, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany, ⁷¹Department of Child and Adolescent Psychiatry, University Hospital Essen, University of Duisburg-Essen, Essen, Germany, ⁷²1st Psychiatric Department, National and Kapodistrian University of Athens, Medical School, Eginition Hospital, Athens, Greece, ⁷³INSERM U1266, Institute of Psychiatry and Neuroscience of Paris, Paris, France, ⁷⁴CMME (GHU Paris Psychiatrie et Neurosciences), Paris Descartes University, Paris, France, ⁷⁵Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA, ⁷⁶Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia,

Pennsylvania, USA, ⁷⁷Institute of Translational Genomics, Helmholtz Zentrum München - German Research Centre for Environmental Health, Neuherberg, Germany, ⁷⁸Department of Adult Psychiatry, Poznan University of Medical Sciences, Poznan, Poland, ⁷⁹Zorg op Orde, Delft, The Netherlands, ⁸⁰Department of General Internal Medicine and Psychosomatics, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany, ⁸¹Department of Psychiatry, and Genetics and Genomics Sciences, Division of Psychiatric Genomics, Icahn School of Medicine at Mount Sinai, New York, New York, USA, ⁸²Biological Psychiatry Laboratory, McLean Hospital/Harvard Medical School, Boston, Massachusetts, USA, ⁸³Eating Disorders Unit, Parklandklinik, Bad Wildungen, Germany, ⁸⁴Department of Molecular Life Science, Division of Basic Medical Science and Molecular Medicine, School of Medicine, Tokai University, Isehara, Japan, ⁸⁵Faculty of Health Sciences, Palacky University, Olomouc, Czech Republic, ⁸⁶Rheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, Spain, ⁸⁷Department of Psychiatry, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁸⁸Institute of Public Health and Clinical Nutrition, Department of Clinical Nutrition, University of Eastern Finland, Kuopio, Finland, ⁸⁹Eating Disorders Unit, Department of Child and Adolescent Psychiatry, Medical University of Vienna, Vienna, Austria, ⁹⁰Groningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, The Netherlands, ⁹¹Centre for Addiction and Mental Health, Toronto, Ontario, Canada, ⁹²Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada, ⁹³Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada, ⁹⁴Department of Public Health, University of Helsinki, Helsinki, Finland, ⁹⁵Institute of Applied Health Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK, ⁹⁶Department of Psychiatry, Seoul Paik Hospital, Inje University, Seoul, Korea, ⁹⁷Department of Psychology, Michigan State University, East Lansing, Michigan, USA, ⁹⁸Department of Mental Disorders, Norwegian Institute of Public Health, Oslo, Norway, ⁹⁹Department of Clinical Science, Norwegian Centre for Mental Disorders Research (NORMENT), University of Bergen, Bergen, Norway, ¹⁰⁰Dr. Einar Martens Research Group for Biological Psychiatry, Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway, ¹⁰¹Department of Clinical Medicine, Laboratory Building, Haukeland University Hospital, Bergen, Norway, ¹⁰²The Chicago School of Professional Psychology, Washington DC Campus, USA, ¹⁰³Department of Cancer Epidemiology and Prevention, M Skłodowska-Curie Cancer Center - Oncology Center, Warsaw, Poland, ¹⁰⁴BESE Division, King Abdullah University of Science and Technology, Thuwal, Saudi Arabia, ¹⁰⁵Department of Psychiatry, University of Lausanne-University Hospital of Lausanne (UNIL-CHUV), Lausanne, Switzerland, ¹⁰⁶Department of Psychiatry, University of Campania "Luigi Vanvitelli", Naples, Italy, ¹⁰⁷Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland, ¹⁰⁸Department of Paediatric Laboratory Medicine, Division of Genome Diagnostics, The Hospital for Sick Children, Toronto, Ontario, Canada, ¹⁰⁹NORMENT KG Jebsen Centre, Division of Mental Health and Addiction, University of Oslo, Oslo University Hospital, Oslo, Norway, ¹¹⁰Department of Psychiatry, University College Cork, Cork, Ireland, ¹¹¹Eist Linn Adolescent Unit, Bessborough, Health Service Executive South, Cork, Ireland, ¹¹²Institute of Molecular and Cell Biology, University of Tartu, Tartu, Estonia, ¹¹³Molecular Epidemiology Section (Department of Biomedical Datasciences), Leiden University Medical Centre, Leiden, The Netherlands, ¹¹⁴Department of Psychiatry, Faculty of Medicine, University

of Geneva, Geneva, Switzerland, ¹¹⁵Division of Child and Adolescent Psychiatry, Geneva University Hospital, Geneva, Switzerland, ¹¹⁶National Center for PTSD, VA Boston Healthcare System, Boston, Massachusetts, USA, ¹¹⁷Department of Psychiatry, Boston University School of Medicine, Boston, Massachusetts, USA, ¹¹⁸Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Salerno, Italy, ¹¹⁹Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Florence, Italy, ¹²⁰Kartini Clinic, Portland, Oregon, USA, ¹²¹Center for Neurobehavioral Genetics, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, California, USA, ¹²²Department of Psychiatry, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands, ¹²³Division of Rheumatology, Department of Medicine, Center for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ¹²⁴Institute for Molecular Medicine FIMM, HiLIFE, University of Helsinki, Helsinki, Finland, ¹²⁵Center for Human Genome Research, Massachusetts General Hospital, Boston, Massachusetts, USA, ¹²⁶Saint Joan de Déu Research Institute, Saint Joan de Déu Barcelona Children's Hospital, Barcelona, Spain, ¹²⁷Institute of Biomedicine (IBUB), University of Barcelona, Barcelona, Spain, ¹²⁸Department of Genetics, Microbiology and Statistics, University of Barcelona, Barcelona, Spain, ¹²⁹Institute of Clinical Medicine, University of Oslo, Oslo, Norway, ¹³⁰Department of Health Science, University of Florence, Florence, Italy, ¹³¹Department of Biometry, University of Helsinki, Helsinki, Finland, ¹³²Eating Disorders Research and Treatment Center, Department of Child and Adolescent Psychiatry, Faculty of Medicine, Technische Universität Dresden, Dresden, Germany, ¹³³Department of Psychiatry, Neurobiology, Pharmacology, and Biotechnologies, University of Pisa, Pisa, Italy, ¹³⁴Department of Psychiatry, Poznan University of Medical Sciences, Poznan, Poland, ¹³⁵Department of Neurosciences, Padua Neuroscience Center, University of Padova, Padova, Italy, ¹³⁶Institute of Medical Statistics, Computer and Data Sciences, Jena University Hospital, Jena, Germany, ¹³⁷Department of Genetics and Genomic Biology, The Hospital for Sick Children, Toronto, Ontario, Canada, ¹³⁸McLaughlin Centre, University of Toronto, Toronto, Ontario, Canada, ¹³⁹Institute of Psychiatry, Psychology and Neuroscience, Department of Psychological Medicine, King's College London, London, UK, ¹⁴⁰J. Craig Venter Institute (JCVI), La Jolla, California, USA, ¹⁴¹Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria, ¹⁴²Department of Pediatrics and Center of Applied Genomics, First Faculty of Medicine, Charles University, Prague, Czech Republic, ¹⁴³Molecular Epidemiology Section (Department of Medical Statistics), Leiden University Medical Centre, Leiden, The Netherlands, ¹⁴⁴Center for Eating Disorders Ursula, Rivierduinen, Leiden, The Netherlands, ¹⁴⁵Department of Psychiatry, Leiden University Medical Centre, Leiden, The Netherlands, ¹⁴⁶Department of Child and Adolescent Psychiatry, Poznan University of Medical Sciences, Poznan, Poland, ¹⁴⁷IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy, ¹⁴⁸Department of Environmental Epidemiology, Nofer Institute of Occupational Medicine, Lodz, Poland, ¹⁴⁹Department of Psychiatry, University of Naples SUN, Naples, Italy, ¹⁵⁰Department of Psychiatry, University of Perugia, Perugia, Italy, ¹⁵¹Brain Sciences Department, Stremble Ventures, Limassol, Cyprus, ¹⁵²Adolescent Health Unit, Second Department of Pediatrics, "P. & A. Kyriakou" Children's Hospital, University of Athens, Athens, Greece, ¹⁵³Pediatric Intensive Care Unit, "P. & A. Kyriakou" Children's Hospital, University of Athens,

Athens, Greece, ¹⁵⁴Faculty of Social and Behavioral Sciences, Utrecht University, Utrecht, The Netherlands, ¹⁵⁵Department of Internal Medicine VI, Psychosomatic Medicine and Psychotherapy, University Medical Hospital Tuebingen, Tuebingen, Germany, ¹⁵⁶BioRealm, LLC, Walnut, California, USA, ¹⁵⁷Oregon Research Institute, Eugene, Oregon, USA, ¹⁵⁸Christchurch Health and Development Study, University of Otago, Christchurch, New Zealand, ¹⁵⁹The Center for Eating Disorders at Sheppard Pratt, Baltimore, Maryland, USA, ¹⁶⁰Department of Psychiatry, Weill Cornell Medical College, New York, New York, USA, ¹⁶¹Eating Recovery Center, Denver, Colorado, USA, ¹⁶²Department of Psychiatry, University of California San Diego, La Jolla, California, USA, ¹⁶³Department of Psychiatry and Behavioral Science, University of North Dakota School of Medicine and Health Sciences, Fargo, North Dakota, USA, ¹⁶⁴Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia, ¹⁶⁵Biostatistics and Computational Biology Unit, University of Otago, Christchurch, New Zealand, ¹⁶⁶Department of Psychiatry and Biobehavioral Science, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, California, USA, ¹⁶⁷David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA, ¹⁶⁸Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, ¹⁶⁹Centre for Mental Health, University Health Network, Toronto, Ontario, Canada, ¹⁷⁰Program for Eating Disorders, University Health Network, Toronto, Ontario, Canada, ¹⁷¹The Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Aarhus, Denmark, ¹⁷²Centre for Integrative Sequencing, iSEQ, Aarhus University, Aarhus, Denmark, ¹⁷³Bioinformatics Research Centre, Aarhus University, Aarhus, Denmark, ¹⁷⁴Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia, ¹⁷⁵National Centre for Register-Based Research, Aarhus BSS, Aarhus University, Aarhus, Denmark, ¹⁷⁶Centre for Integrated Register-based Research (CIRRAU), Aarhus University, Aarhus, Denmark, ¹⁷⁷Department of Psychological Medicine, University of Otago, Christchurch, New Zealand, ¹⁷⁸Canterbury District Health Board, Christchurch, New Zealand, ¹⁷⁹Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand, ¹⁸⁰Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden, ¹⁸¹Division of Human Genetics, Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA, ¹⁸²Veterans Affairs Connecticut Healthcare System, West Haven, Connecticut, USA, ¹⁸³Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana, USA, ¹⁸⁴Virginia Commonwealth University Alcohol Research Center, Virginia Commonwealth University, Richmond, Virginia, USA, ¹⁸⁵Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, Virginia, USA, ¹⁸⁶Department of Psychiatry, Virginia Commonwealth University, Richmond, Virginia, USA, ¹⁸⁷Psychiatric Genomics and Pharmacogenomics Program, Mayo Clinic, Rochester, Minnesota, USA, ¹⁸⁸Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York, USA, ¹⁸⁹Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA, ¹⁹⁰Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA, ¹⁹¹Department of Psychiatry and Behavioral Sciences, State University of New York Downstate Medical Center, Brooklyn, New York, USA, ¹⁹²Division of Psychiatry, University of Edinburgh, Edinburgh, UK, ¹⁹³Institute of Human Genetics, University

of Bonn School of Medicine & University Hospital Bonn, Bonn, Germany, ¹⁹⁴Department of Psychiatry, University of Utah, Salt Lake City, Utah, USA, ¹⁹⁵Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany, ¹⁹⁶Laboratory of Neurogenetics, NIH/NIAAA, Bethesda, Maryland, USA, ¹⁹⁷Institute of Human Genetics, School of Medicine & University Hospital Bonn, University of Bonn, Bonn, Germany, ¹⁹⁸Human Genomics Research Group, Department of Biomedicine, University of Basel, Basel, Switzerland, ¹⁹⁹Institute of Medical Genetics and Pathology, University Hospital Basel, University Hospital Basel, Basel, Switzerland, ²⁰⁰Department of Biological Psychology, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands, ²⁰¹Turku Institute for Advanced Studies, University of Turku, Turku, Finland, ²⁰²Department of Psychology and Logopedics, University of Helsinki, Helsinki, Finland, ²⁰³Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA, ²⁰⁴Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA, ²⁰⁵Division of Psychiatry, Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK, ²⁰⁶Department of Integrative Physiology, University of Colorado Boulder, Boulder, Colorado, USA, ²⁰⁷Department of Psychiatry and Behavioral Sciences, Henri Begleiter Neurodynamics Laboratory, SUNY Downstate Medical Center, Brooklyn, New York, USA, ²⁰⁸Department of Psychiatry, Amsterdam Public Health Research Institute, VU University Medical Center/GGz inGeest, Amsterdam, The Netherlands, ²⁰⁹Department of Genetics, Washington University School of Medicine, Saint Louis, Missouri, USA, ²¹⁰NIH/NIAAA, Office of the Clinical Director, Bethesda, Maryland, USA, ²¹¹Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, Massachusetts, USA, ²¹²Department of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University, Cambridge, Massachusetts, USA, ²¹³Department of Sociology, Harvard University, Cambridge, Massachusetts, USA, ²¹⁴Department of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado, USA, ²¹⁵Institute of Behavioral Science, University of Colorado, Boulder, Colorado, USA, ²¹⁶Department of Sociology, University of Colorado, Boulder, Colorado, USA, ²¹⁷Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA, ²¹⁸Department of Psychiatry, University of Vermont Medical Center, Burlington, Vermont, USA, ²¹⁹Department of Medicine, Division of Biostatistics, Washington University School of Medicine, Saint Louis, Missouri, USA, ²²⁰Department of Psychiatry, University of Mainz, Mainz, Germany, ²²¹National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia, ²²²Stanford University Graduate School of Education, Stanford University, Stanford, California, USA, ²²³Department of Psychiatry and Psychotherapy, University of Düsseldorf, Duesseldorf, Germany, ²²⁴MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK, ²²⁵Max-Planck-Institute of Psychiatry, Munich, Germany, ²²⁶Department of Psychology, University of Minnesota, Minneapolis, Minnesota, USA, ²²⁷Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany, ²²⁸Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany, ²²⁹Department of Psychiatry, University of Iowa Roy J and Lucille A Carver College of

Medicine, Iowa City, Iowa, USA,²³⁰Addictions Department, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK,²³¹Department of Psychiatry, University of Bonn, Bonn, Germany,²³²Department of Public Health Solutions, National Institute for Health and Welfare, Helsinki, Finland,²³³Department of Statistical Genetics, Max-Planck-Institute of Psychiatry, München, Germany,²³⁴Aberdeen Biomedical Imaging Centre, School of Medicine, Medical Sciences & Nutrition, University of Aberdeen, Foresterhill, Aberdeen, UK,²³⁵Department of Psychiatry, Indiana University School of Medicine, Indianapolis, Indiana, USA,²³⁶Department of Psychiatry, Psychotherapy and Psychosomatics, Martin-Luther-University Halle-Wittenberg, Herborn, Germany,²³⁷Department of Psychiatry and Psychotherapy, Vitos Hospital Herborn, Herborn, Germany,²³⁸School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA,²³⁹Department of Psychiatry and Psychotherapy, University of Regensburg Psychiatric Health Care Aargau, Regensburg, Germany,²⁴⁰LVR-Hospital Essen, Medical Faculty, University of Duisburg-Essen, Essen, Germany,²⁴¹Department of Addictive Behaviour and Addiction Medicine, Medical Faculty, University of Duisburg-Essen, Essen, Germany,²⁴²Department of Psychiatry and Psychotherapy, Medical Faculty, University of Duisburg-Essen, Essen, Germany,²⁴³Medical Park Chiemseeblick in Bernau-Felden, Ludwig-Maximilians-University, Bernau am Chiemsee, Germany,²⁴⁴Psychiatric Hospital, Ludwig-Maximilians-University, Bernau am Chiemsee, Germany,²⁴⁵Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany,²⁴⁶Department of Psychiatry, Psychiatric Hospital, Ludwig-Maximilians-University, Munich, Germany,²⁴⁷Department of Sociology, University of Utah, Salt Lake City, Utah, USA,²⁴⁸Department of Psychology, University of California San Diego, USA,²⁴⁹Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina, USA,²⁵⁰Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, Illinois, USA,²⁵¹NIAAA Intramural Research Program, Bethesda, Maryland, USA,²⁵²Department of General Practice and Primary Health Care, University of Helsinki, Helsinki, Finland,²⁵³National Institute for Health and Welfare, Helsinki, Finland,²⁵⁴Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, USA,²⁵⁵Department of Ophthalmology, Boston University School of Medicine, Boston, Massachusetts, USA,²⁵⁶Department of Epidemiology, School of Public Health, Boston University, Boston, Massachusetts, USA,²⁵⁷Department of Biostatistics, School of Public Health, Boston University, Boston, Massachusetts, USA,²⁵⁸Office of the Clinical Director, NIH/NIAAA, Bethesda, Maryland, USA,²⁵⁹Center for Omics Discovery and Epidemiology, Behavioral Health Research Division, RTI International, Research Triangle Park, North Carolina, USA,²⁶⁰Department of Sociology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA,²⁶¹Carolina Population Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA,²⁶²Department of Psychiatry, University of Connecticut School of Medicine, Farmington, Connecticut, USA,²⁶³Institute for Behavioral Genetics, University of Colorado Boulder, Boulder, Colorado, USA,²⁶⁴Department of Psychiatry, University of Colorado Denver, Aurora, Colorado, USA,²⁶⁵Fellow Program, RTI International, Research Triangle Park, North Carolina, USA,²⁶⁶Center for Studies of Addiction, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA,²⁶⁷VISN 4 MIRECC, Crescenz VAMC, Philadelphia, Pennsylvania, USA,²⁶⁸Department of Molecular, Cellular, and Developmental

Biology, University of Colorado Boulder, Boulder, Colorado, USA, ²⁶⁹Peter Boris Centre for Addictions Research, McMaster University/St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada, ²⁷⁰Michael G. DeGroot Centre for Medicinal Cannabis Research, McMaster University/St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada, ²⁷¹Institute for Genomic Medicine, University of California San Diego, La Jolla, California, USA, ²⁷²Department of Psychiatry, Amsterdam UMC, VU University and GGZinGeest, Amsterdam, The Netherlands, ²⁷³Department of Psychological & Brain Sciences, Indiana University Bloomington, Bloomington, Indiana, USA, ²⁷⁴School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA, ²⁷⁵Department of Biostatistics, Yale School of Public Health, Yale University, New Haven, Connecticut, USA, ²⁷⁶School of Psychology, Flinders University, Adelaide, South Australia, Australia, ²⁷⁷Queensland Brain Institute, University of Queensland, Brisbane, Queensland, Australia, ²⁷⁸Department of Genetics, Yale School of Medicine, New Haven, Connecticut, USA, ²⁷⁹Department of Neuroscience, Yale School of Medicine, New Haven, Connecticut, USA, ²⁸⁰Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

*Joint last authors

Correspondence: Melissa A. Munn-Chernoff, PhD
Department of Psychiatry
University of North Carolina at Chapel Hill
101 Manning Drive, Campus Box 7160
Chapel Hill, NC 27599
Phone: 984-974-3788
Email: melissa_chernoff@med.unc.edu

Running Head: Eating and Substance Use

Abstract: 246 words

Text: 4,813 words

References: 55

Tables: 2

Figures: 1

Abstract

Eating disorders and substance use disorders frequently co-occur. Twin studies reveal shared genetic variance between liabilities to eating disorders and substance use, with the strongest associations between symptoms of bulimia nervosa (BN) and problem alcohol use (genetic correlation [r_g], twin-based=0.23-0.53). We estimated the genetic correlation between eating disorder and substance use and disorder phenotypes using data from genome-wide association studies (GWAS). Four eating disorder phenotypes (anorexia nervosa [AN], AN *with* binge-eating, AN *without* binge-eating, and a BN factor score), and eight substance-use-related phenotypes (drinks per week, alcohol use disorder [AUD], smoking initiation, current smoking, cigarettes per day, nicotine dependence, cannabis initiation, and cannabis use disorder) from eight studies were included. Significant genetic correlations were adjusted for variants associated with major depressive disorder (MDD). Total sample sizes per phenotype ranged from ~2,400 to ~537,000 individuals. We used linkage disequilibrium score regression to calculate single nucleotide polymorphism-based genetic correlations between eating disorder and substance-use-related phenotypes. Significant positive genetic associations emerged between AUD and AN ($r_g=0.18$; false discovery rate $q=0.0006$), cannabis initiation and AN ($r_g=0.23$; $q<0.0001$), and cannabis initiation and AN *with* binge-eating ($r_g=0.27$; $q=0.0016$). Conversely, significant negative genetic correlations were observed between three non-diagnostic smoking phenotypes (smoking initiation, current smoking, and cigarettes per day) and AN *without* binge-eating ($r_{gs}=-0.19$ to -0.23 ; $q_s<0.04$). The genetic correlation between AUD and AN was no longer significant after co-varying for MDD loci. The patterns of association between eating disorder- and substance-use-related phenotypes highlights the potentially complex and substance-specific relationships between these behaviors.

Keywords: eating disorders; genetic correlation; genome-wide association

Shared Genetic Risk between Eating Disorder- and Substance-Use-Related Phenotypes: Evidence from Genome-Wide Association Studies

A well-established phenotypic association exists between eating disorder and substance use phenotypes, with evidence for specific relations between particular types of eating disorders and substance use disorders. The prevalence of an alcohol use disorder (AUD) is greater among individuals with bulimia nervosa (BN) and binge-eating disorder (BED) than individuals with anorexia nervosa (AN) or healthy controls (Gadalla and Piran, 2007, Root *et al.*, 2010). Similarly, individuals with BN or BED are at increased risk for smoking, nicotine dependence (ND) (Solmi *et al.*, 2016, Wiederman and Pryor, 1996), and cannabis use (Krug *et al.*, 2008, Wiederman and Pryor, 1996) compared with individuals with AN or healthy controls, though these results are not consistent (Root *et al.*, 2010). Importantly, women with the binge-eating/purging subtype of AN report a higher prevalence of AUD, smoking, ND, and cannabis use than women with the restricting subtype of AN (Anzengruber *et al.*, 2006, Krug *et al.*, 2008, Root *et al.*, 2010). Thus, binge eating—a transdiagnostic symptom defined as eating a large amount of food in a short period of time while experiencing loss of control—may be a key component of the observed association.

However, prior research has only partially addressed whether binge eating is the critical eating disorder symptom in the comorbidity, especially across different milestones of substance use (i.e., initiation through substance use disorder) and across a variety of substances (i.e., alcohol, nicotine, and cannabis). It is crucial to elucidate shared sources for these associations because of the increased morbidity and mortality associated with comorbid presentations (Duncan *et al.*, 2006, Franko *et al.*, 2013) and because improvements in one disorder may exacerbate (or weaken) symptoms of the other disorder (Center on Addiction and Substance

Abuse, 2003). Refining our understanding of these associations could improve prevention and treatment approaches for these debilitating disorders, their comorbidity, and their sequelae.

Accumulating findings from twin studies implicate shared genetic factors between eating disorder- and substance-use-related phenotypes. The strongest reported association is between BN symptoms, including binge eating, and problem alcohol use (Munn-Chernoff and Baker, 2016), with a genetic correlation (r_g) ranging from 0.23 to 0.53 (Baker *et al.*, 2010, Baker *et al.*, 2017, Munn-Chernoff *et al.*, 2013, Munn-Chernoff *et al.*, 2015, Slane *et al.*, 2012, Trace *et al.*, 2013). Although there has been less focus on the genetic associations between BN symptoms and regular smoking and BN symptoms and illicit drug use disorder, twin-based r_g s of 0.35 and approximately 0.38, respectively, have been reported (Baker *et al.*, 2007, Baker *et al.*, 2010). A paucity of information exists regarding whether less problematic aspects of substance use exhibit a significant r_g with eating disorder phenotypes. The impact of genetic factors influencing this comorbidity may significantly increase once an individual has progressed to problematic alcohol use, as genetic effects are more prominent in problem substance use, such as abuse and dependence, than with the initiation and general use of substances (Heath *et al.*, 1997, Rhee *et al.*, 2003, True *et al.*, 1997, van den Bree *et al.*, 1998). No study has comprehensively examined a range of eating disorder- and substance-use-related phenotypes to determine whether the r_g varies with different aspects of substance use and whether the r_g varies depending on the eating disorder and substance examined.

Recent advances in genomic methods allow for an assessment of r_g using existing genome-wide association study (GWAS) summary statistics. Unlike twin studies, these genome-wide methods allow for use of unrelated cases and controls, which typically yield large sample sizes (i.e., in the tens to hundreds of thousands). One such method is linkage disequilibrium

score regression (LDSC; Bulik-Sullivan *et al.*, 2015a, Bulik-Sullivan *et al.*, 2015b), which estimates single-nucleotide polymorphism (SNP)-based heritability and r_g between phenotypes. Of particular relevance to low prevalence phenotypes, such as AN, estimation of SNP-based r_g does not require both phenotypes to be measured in the same individual, meaning that independent studies assessing only one phenotype can be jointly examined.

Thus, the aim of the current study is to estimate SNP-based r_g s between eating disorder- and substance-use-related phenotypes based upon summary statistics from the largest published eating disorder GWAS and existing GWAS encompassing a range of substance-use-related phenotypes. This study examines shared SNP-based genetic risk between eating disorder and multiple substance-use-related phenotypes (i.e., alcohol, nicotine, and cannabis), using robust data from twin studies to shape our expectations. First, we hypothesize that the strongest SNP-based r_g will be between eating disorder phenotypes that have binge eating as a core symptom and alcohol use phenotypes (Munn-Chernoff and Baker, 2016). Second, we hypothesize that for binge-eating-related phenotypes, the SNP-based r_g will be lowest when examining typical alcohol consumption and highest when assessing AUD (Munn-Chernoff and Baker, 2016). Because we have less information from twin studies about genetic associations between liabilities to eating disorders and tobacco (nicotine) and cannabis use-related phenotypes, we do not forward any hypotheses for these substances. Finally, prior studies document robust genetic associations between major depressive disorder (MDD) and both eating disorders and substance-use-related phenotypes (e.g., Kranzler *et al.*, 2019; Liu *et al.*, 2019; Watson *et al.*, 2019). We hypothesized that r_g s between eating disorders and substance use and disorder would be attenuated when accounting for variants associated with MDD. Findings from this study could yield important information about this clinically challenging pattern of comorbidity

(Gregorowski *et al.*, 2013), ultimately suggesting biologically informed prevention efforts and improved treatments for patients presenting with these dual diagnoses.

Method

Participants

We included summary statistics from two existing GWAS of eating disorder phenotypes where participants were primarily of European ancestry (Wade *et al.*, 2013, Watson *et al.*, 2019) and using data from individuals of European ancestry from six existing GWAS of substance-use-related phenotypes (Demontis *et al.*, 2019, Hancock *et al.*, 2017, Kranzler *et al.*, 2019, Liu *et al.*, 2019, Pasman *et al.*, 2018, Walters *et al.*, 2018). The eating disorder phenotypes (**Table 1**) included a diagnosis of AN (which was further parsed into AN *with* binge-eating or AN *without* binge-eating), and a BN factor score derived from the Eating Disorder Examination (EDE; Fairburn and Cooper, 1993). The EDE is a well-established, structured clinical interview used to determine eating disorder diagnoses. We did not examine BN or BED diagnoses because there are currently no published GWAS for either disorder; thus, the EDE-BN factor score represents the closest to a GWAS of BN available. Substance-use-related phenotypes ranged from typical use (e.g., drinks per week, smoking initiation, and cannabis initiation) to substance use disorder (i.e., AUD, ND, and cannabis use disorder [CUD]). Sample sizes for the phenotypes ranged from 2,442 (BN factor) to 537,349 (drinks per week) individuals. **Table 2** provides individual study details.

Insert Tables 1 and 2 Here

Statistical Analysis

We used LDSC (Bulik-Sullivan *et al.*, 2015a, Bulik-Sullivan *et al.*, 2015b) to evaluate SNP-based genetic correlations (r_g) between samples. This method uses the linkage disequilibrium (LD) structure of the genome to estimate the distribution of effect sizes for individual SNPs as a function of their LD score. Under a polygenic model, causal SNPs are likely to be overrepresented in higher LD score bins (i.e., including additional SNPs in high LD) such that associations with SNPs in these LD bins will make stronger contributions to the phenotypic variation under study. This polygenic distribution of effect sizes across LD score bins provides an estimate of SNP-based heritability, i.e., the proportion of phenotypic variance that is attributable to the aggregate effects of genome-wide SNPs. The correlation of effect sizes across LD bins between two phenotypes then provides an estimate of SNP-based r_g .

Genetic correlations range from -1 to +1, where the sign indicates that the same genetic factors are contributing to variation in the target traits in *opposite* or *same* directions, respectively. The LDSC intercept for the genetic covariance provides evidence about sample overlap across two traits. SNPs (MAF>0.01) found in the HapMap3 EUR population were used to calculate LD scores. We used the false discovery rate (FDR; Benjamini and Hochberg, 1995) to correct for multiple testing ($n=66$ tests; $q<0.05$). Finally, post-hoc analyses examined whether significant differences between two r_g s existed, using the jackknife procedure implemented through LDSC (Bulik-Sullivan *et al.*, 2015b).

For significant r_g s detected in LDSC, multi-trait-based conditional and joint analysis using GWAS summary data (mtCOJO; Zhu *et al.*, 2018) was used to condition both input GWAS (e.g., AN and AUD) for variants associated with MDD at $p<5\times 10^{-7}$ (Wray *et al.*, 2018). LDSC was used to compute r_g s using the resulting genome-wide summary statistics for each trait

after adjustment for MDD variants to examine whether conditioning on MDD would affect the observed genetic relationships. Further, for significant r_g s detected in LDSC where both the individual eating disorder- and substance-use-related phenotypes each had ~10 or more significant GWAS SNPs (Zhu *et al.*, 2018), bidirectional Mendelian randomization (MR) analyses (Smith and Ebrahim, 2003) were conducted using Generalised Summary-data-based Mendelian Randomisation (GSMR; Zhu *et al.*, 2018) to preliminarily investigate potentially causal relationships between liabilities to these phenotypes. As GSMR requires a reference sample with individual genotypes to account for LD, we used the 1000 Genomes Phase 3 European ancestries sample as our reference panel (1000 Genomes Project Consortium *et al.*, 2015). SNPs with evidence of horizontal pleiotropy were excluded (using the HEIDI-Outlier method; default p -value threshold=0.01). We only included genome-wide significant SNPs ($p < 5 \times 10^{-8}$) as possible instruments, and SNPs were clumped to ensure independence (i.e., amongst a set of genome-wide significant SNPs correlated at $r^2 > 0.05$ within a 1-Mb window, only the SNP with the lowest p -value was retained). As MR analyses are sensitive to sample overlap, we scanned the published papers to determine which samples were included in the discovery GWAS, and any known samples in common across the two discovery GWAS were excluded from the eating disorder GWAS and summary statistics were regenerated for MR analyses.

Results

The overall SNP-based heritability for the eating disorder phenotypes ranged from 0.20 to 0.39, whereas the corresponding heritabilities for the substance-use-related phenotypes ranged from 0.03 to 0.35 (**Supplemental Table 1**). **Figure 1** and **Supplemental Table 1** show the

genetic correlations (r_g s) between all four eating disorder phenotypes and eight substance-use-related phenotypes. Broadly speaking, there were significant r_g s across substance-use-related phenotypes, ranging from 0.21 (AUD and cigarettes per day) to 0.70 (drinks per week and AUD). Cannabis initiation risk was not significantly genetically correlated with cigarettes per day or ND. For the remaining results, we focus on previously unexplored associations of interest in this study—correlations between eating disorder- and substance-use-related phenotypes. For these associations, the genetic covariance intercepts ranged from -0.03 (standard error [SE]=0.01; AN and cannabis initiation) to 0.01 (SE=0.01; AN and CUD), indicating some sample overlap (or low-level confounding) existed (Yengo *et al.*, 2018), although the LDSC approach parses this overlap from the r_g estimation.

Significant positive r_g s were observed for alcohol- and cannabis-use-related phenotypes. First, the r_g was significant between AN and AUD ($r_g=0.18$; SE=0.05; $q=0.0006$), but not between AN and drinks per week ($r_g=0.01$; SE=0.03; $q=0.91$), suggesting that genetic factors that increase risk for AN also increase risk for AUD, but little evidence exists for shared genetic risk between AN and typical alcohol consumption. These two correlations significantly differed from each other (z-score=3.51, $p=0.0005$). Intriguingly, there was a significant difference in r_g s for AN and AUD versus AN *without* binge-eating and AUD (z-score=2.28, $p=0.02$), but not for AN and AUD versus AN *with* binge-eating and AUD (z-score=0.23, $p=0.82$). No significant association between the BN factor, which included items pertaining to both binge eating and compensatory behaviors, and either alcohol-use-related phenotype was observed.

Second, the significant r_g between AN and cannabis initiation was 0.23 (SE=0.04, $q<0.0001$), and the significant r_g between AN *with* binge-eating and cannabis initiation was 0.27 (SE=0.08, $q=0.0017$), indicating that genetic factors that increase the risk for AN also increase

the risk for cannabis initiation. However, cannabis initiation was not significantly correlated with the BN factor ($r_g=0.15$, $SE=0.18$, $q=0.57$) or with AN *without* binge-eating ($r_g=0.10$, $SE=0.08$, $q=0.31$). No significant associations were observed between any eating disorder phenotype and CUD ($r_{gs}=-0.08-0.23$; $SEs=0.01$; $qs\leq 0.57$). Post-hoc analyses revealed significant differences in the r_g s for AN and cannabis initiation versus AN and CUD ($z\text{-score}=2.70$, $p=0.01$). However, the r_g between AN *with* binge-eating and cannabis initiation, while significant, was statistically different from the r_g between AN *with* binge-eating and CUD.

Conversely, for smoking phenotypes, significant correlations were only observed for the AN *without* binge-eating subtype. Smoking initiation ($r_g=-0.21$, $SE=0.06$, $q=0.0006$), current smoking (referred to as smoking cessation in Liu *et al.*, 2019)¹ ($r_g=-0.19$, $SE=0.08$, $q=0.03$), and cigarettes per day ($r_g=-0.23$, $SE=0.07$, $q=0.003$) were significantly and negatively associated with AN *without* binge-eating. Although the correlation between ND and AN *without* binge-eating was in the same direction as the other smoking phenotypes, it was not significant ($r_g=-0.22$, $SE=0.12$, $q=0.14$). The r_{gs} for AN diagnosis and each of the three non-diagnostic smoking traits versus AN *without* binge-eating and these same smoking traits all differed significantly from each other ($z\text{-scores}$ ranged from -3.22 to -2.11 ; $p\text{-values}\leq 0.04$).

After conditioning the AN and AUD GWAS summary statistics for the MDD GWAS summary statistics, the positive r_g between AN and AUD was attenuated ($r_g=0.07$; $SE=0.05$, $q=0.125$; **Supplemental Table 2**) and significantly lower than the unadjusted r_g ($z\text{-score}=2.48$, $p=0.01$). In contrast, after conditioning the AN *with* binge-eating and cannabis initiation GWAS for MDD, the resulting r_g was marginally smaller but remained significant after correction for multiple tests ($r_g=0.21$, $SE=0.08$, $q=0.016$). After conditioning for the MDD GWAS, r_{gs} between

¹ In Liu *et al.* (2019), the phenotype is noted as “smoking cessation”, where current smokers were coded as 2 and former smokers were coded as 1. Because the comparison group is “current smokers”, we have renamed this phenotype as “current smoking” for clarification and ease of interpretation across all smoking phenotypes.

AN *without* binge-eating and smoking initiation, current smoking, and cigarettes per day remained significant and modestly increased in magnitude (r_g s=-0.27 to -0.31; SEs=0.05 to 0.09; q s<0.0009).

Because the AN GWAS and cannabis initiation GWAS each identified eight significant loci (Pasman *et al.*, 2018, Watson *et al.*, 2019), and the two studies comprising the AUD sample identified 10 significant loci (Kranzler *et al.*, 2019, Walters *et al.*, 2018), we also conducted exploratory follow-up MR analyses for AN-AUD and AN-cannabis initiation to examine whether there might be evidence of a causal relationship, given their significant r_g . We used summary statistics from a subset of the AN GWAS that did not include the UK Biobank cohort for the AN-cannabis initiation analysis, as this cohort overlapped with the cannabis initiation sample (AN subset without the UK Biobank cohort, $N_{cases}=16,224$, $N_{controls}=52,460$). We did not obtain an estimate for the cannabis initiation to AN direction of effect because only four SNPs were available after clumping, all of which were excluded for potential pleiotropy by the HEIDI-outlier analysis. There was no evidence of a causal relationship for any comparison ($p>0.05$; see **Supplemental Table 3**).

Discussion

Using existing GWAS data, we investigated genetic associations between liabilities to four eating disorder and eight substance-use-related phenotypes spanning initiation and typical use to substance use disorder. We found differential patterns of association between the two diagnostic categories for eating disorders, suggesting that differences between AN subtypes with substance-use-related phenotypes may point toward substance-specific genetic relationships. Additionally, there may be some degree of symptom overlap contributing to these associations.

Three main patterns emerged. First, in line with prior twin studies, we observed a positive genetic correlation (r_g) between problem alcohol use (i.e., AUD) and AN diagnosis. Second, we estimated positive r_g s between cannabis initiation and AN diagnosis, as well as cannabis initiation and the AN *with* binge-eating subtype. This is a novel finding not previously examined in twin research. The positive genetic associations suggest that some genetic loci are influencing these traits in the same direction. Second, negative r_g s emerged between the three smoking phenotypes from the GWAS & Sequencing Consortium of Alcohol and Nicotine use (GSCAN) cohort and AN *without* binge-eating, but not with the other three eating disorder phenotypes. These negative r_g s indicate that some of the loci influencing the liability to these eating disorder and smoking phenotypes are shared, but are affecting the liability to these traits in opposite directions. Indeed, r_g s cannot identify specific loci or underlying mechanisms that contribute to the shared risk. Nevertheless, the results provide initial evidence for differential genetic associations between the liability to varying eating disorder- and substance-use-related phenotypes.

Based on findings from twin studies, we hypothesized that: 1) the strongest SNP-based r_g would be between eating disorder phenotypes that have binge eating as a core symptom and alcohol use phenotypes; and 2) a significant positive r_g between eating disorder phenotypes with binge eating as a key symptom and AUD would emerge. In line with these hypotheses, we found a significant genetic association between AUD and AN diagnosis, but not between typical alcohol consumption (i.e., drinks per week) and AN. No twin study has examined genetic associations between AN and alcohol-use-related phenotypes, and previous studies (Walters *et al.*, 2018, Watson *et al.*, 2019) using LDSC have not reported significant r_g s between these traits. That we found a significant association most likely reflects the larger AN sample size in our study (from

3,495 cases and 10,982 controls to 16,992 cases and 55,525 controls), as well as combining two large existing GWAS of AUD, emphasizing the importance of increasing sample sizes for GWAS.

Importantly, the r_g between AN and AUD was not robust to the adjustment for MDD-associated variants. MDD is amongst the most prominent comorbidities in individuals with AN and AUD (American Psychological Association, 2013), and GWAS for both traits document strong r_g s between MDD and these disorders (Kranzler *et al.*, 2019; Walters *et al.*, 2019; Watson *et al.*, 2019). Our results indicate that the three disorders share genetic underpinnings. We cannot discount the possibility of a genetic relationship between AN and AUD that is distinct from MDD; however, much larger sample sizes may be required to detect such an association.

Intriguingly, although we did not detect a significant r_g for AN *with* binge-eating with AUD, the point estimate for the r_g between AUD and AN *with* binge eating was similar to that for AUD and AN diagnosis (0.17 vs. 0.18, respectively) and higher than AUD and AN *without* BE (0.01). Sample sizes for these AN subtypes were smaller than for AN diagnosis; however, the two subtypes included approximately equal numbers of cases and controls. Indeed, binge eating was assessed in such a way that we were unable to tease apart purging behaviors, and AN diagnosis is heterogenous even within subtypes. Therefore, binge eating may be one plausible key component of the observed genetic association. For example, binge eating has been shown to activate brain reward circuitry in a similar manner to substances (Kaye *et al.*, 2013, Volkow *et al.*, 2013), and administration of naltrexone, an opioid antagonist approved by the U.S. Food and Drug Administration for the treatment of AUD (Kranzler and Soyka, 2018), has been shown to reduce the frequency of binge-eating episodes among individuals with an eating disorder (Jonas and Gold, 1988, Stancil *et al.*, in press). We did not detect a significant r_g with the BN factor

score as well, although that GWAS was relatively underpowered. Thus, our findings highlight the importance of expanding GWAS to include BN and BED, where a core symptom of both disorders is binge eating, to elucidate whether binge eating is a critical eating disorder symptom in the comorbidity with AUD and to home in on the relevant shared mechanisms.

The significant genetic associations between cannabis initiation and AN are novel, yet consistent with the negative genetic association between cannabis use and BMI, and with observational (Pasman *et al.*, 2018) and experimental (Di Marzo and Matias, 2005, Volkow *et al.*, 2017) studies regarding the role of endocannabinoids in appetite regulation, energy expenditure, stress, and reward. One of the principal psychoactive agents of cannabis, delta-9-tetrahydrocannabinol (THC), a partial agonist of the endogenous cannabinoid 1 (CB1) receptor, is presumed to be orexigenic and may acutely increase appetite and food intake, contributing to its potential role as an appetite stimulant in patients with an anorexia or cachexia syndrome (Reuter and Martin, 2016) due to a disease (e.g., HIV AIDS) or in response to treatment (e.g., chemotherapy). An antagonist of the CB1 receptor was previously tested as a highly promising anti-obesity medication (Rimonabant, SR141716). Further, the endocannabinoid anandamide has been shown to be elevated in individuals with acute AN (Monteleone and Maj, 2013), indicating disruption in food-related reward and eating behavior regulation. Animal and human studies have also provided initial evidence for the therapeutic effectiveness of cannabinoid agonists in treating eating disorders (Andries *et al.*, 2014, Avraham *et al.*, 2017). It is also likely that individuals with high genetic liability to AN are less likely to experiment with a substance that has a documented hyperphagia component. Thus, there is evidence of a complex biological relationship between cannabis use and eating disorders, as well as BMI. Nonetheless, the preliminary MR analyses did not provide persuasive support for causal relationships, in either

direction, between genetic liability to cannabis initiation and AN. The small sample sizes and small number of SNPs used as instruments, due to the low number of independent genome-wide significant loci and exclusion of overlapping SNPs that were not ambiguous and palindromic, may have significantly limited power to make causal inferences.

Finally, the significant negative r_g s between three tobacco-smoking phenotypes—smoking initiation, current smoking, and cigarettes per day—and AN *without* binge-eating are intriguing, suggesting that AN *without* binge-eating and tobacco-smoking behaviors are alternate expressions of shared mechanisms. Phenotypic studies are inconsistent about the association between the restricting subtype of AN and smoking. Some studies suggest that individuals with restricting AN have a higher prevalence of various smoking phenotypes than controls (Krug *et al.*, 2008), whereas other studies indicate no significant difference between the two groups (Anzengruber *et al.*, 2006). A recent meta-analysis did not find differences in the odds of lifetime smoking between individuals with AN and healthy controls (Solmi *et al.*, 2016), yet the authors did not assess differences by AN subtype. Individuals with AN may smoke as a way to control or lose weight (White, 2011), and temporary weight gain does occur with smoking cessation (Filozof *et al.*, 2004). However, a positive phenotypic correlation need not be accompanied by a r_g in the same direction (or genetic contributors to the phenotypic association at all). Still, there is plausible support for the negative r_g . Although not significant, a negative r_g between smoking and AN has been reported (Bulik-Sullivan *et al.*, 2015a, Watson *et al.*, 2019). Notably, our study includes individuals from these earlier reports and extends findings by including larger sample sizes for both AN and smoking phenotypes. Unfortunately, there are no twin studies of AN or AN-like traits and smoking with which to compare findings.

One explanation for the negative genetic association is that it is due to a third, underlying variable influencing both AN *without* binge-eating and smoking. We tested for the potential role of variants associated with MDD and found the r_{gs} to be robust to that adjustment. In the largest GWAS of smoking phenotypes, positive r_{gs} were also observed between smoking initiation and cigarettes per day with multiple cardiometabolic traits, including type 2 diabetes and fasting glucose (Liu *et al.*, 2019). These same metabolic traits were negatively genetically correlated with AN (Duncan *et al.*, 2017, Watson *et al.*, 2019). Thus, the patterns of r_{gs} might point to metabolic, rather than psychiatric, factors in influencing the apparent genetic association between smoking phenotypes and AN. However, the associations could also reflect adoption of unhealthy lifestyles that promote obesity and are correlated with smoking. In addition, the r_{gs} between smoking and BMI, as well as AN and BMI, could reflect underlying disinhibitory pathways, as variants associated with BMI show enrichment in the central nervous system (Goodarzi, 2018). The current approach is not designed to disentangle these putative etiological mechanisms, but our findings do encourage careful study of the specific relationships between eating and substance use disorders.

Substance use and substance use disorders are partially distinct, and although excessive substance use is a necessary component of substance use disorders, the latter is associated with psychological and physiological impairment related to excess use and aspects of loss of control over the behavior. Consistent with our findings for alcohol, accumulating evidence suggests that genetic liability to other psychiatric traits (e.g., schizophrenia) is strongly correlated with liability to substance use disorders (e.g., AUD) but not substance use (e.g., alcohol consumption; Kranzler *et al.*, 2019; Liu *et al.*, 2019; Walters *et al.*, 2018). Genetic liability to alcohol use has also been correlated with liabilities to psychiatric disorders (e.g., MDD) in opposite directions

depending on level of involvement (Kranzler *et al.*, 2019). However, we did not find similar elevations in r_g s when contrasting ever smoking and ND, nor comparing cannabis initiation to CUD. It is possible that the lack of genetic overlap between AN and ND, as well as AN and CUD, is related to the relatively modest sample size of those discovery GWAS. A similar non-significant r_g was noted for AUD when the Walters *et al.* (2018) alcohol dependence GWAS was used as the sole source of summary statistics for problem drinking in the current study. Several other explanations for this divergence in findings exist. For instance, for tobacco, the highly addictive nature of nicotine may result in convergence in genomic effects on earlier and later stages of smoking (i.e., a much larger proportion of those who ever smoke become dependent compared with the proportion of those who drink alcohol and develop AUD). For cannabis, given its lower addictive potential, we might have expected stronger associations with CUD than with cannabis initiation. In addition to the considerably smaller sample size of the CUD GWAS, the association with cannabis initiation could also be attributed to the small number of cohorts in that discovery GWAS that included individuals with a high likelihood of CUD. It is also possible that the relationship between AN and cannabis use is distinct and that earlier, but not later stages of cannabis use are genetically related to liability to AN. Future studies should consider the multi-stage nature of substance use and misuse when examining cross-trait correlations.

This is the largest and most comprehensive assessment of shared genetic risk between eating disorder- and substance-use-related phenotypes to date, using existing GWAS data from large cohorts (up to ~537,000 individuals per phenotype). We were able to separately assess approximate AN subtypes (i.e., *with* binge-eating vs. *without* binge-eating) to evaluate the extent to which binge eating, in the context of AN, may share genetic risk with substance-use-related phenotypes. Using these large datasets—many of which are publicly available—allows for the

rapid development of scientific knowledge regarding the underlying etiology of psychiatric disorder and substance use comorbidity. Nevertheless, some limitations exist. First, sample sizes for the BN factor score and CUD GWAS were relatively small compared with the other GWAS, resulting in large standard errors and low power. Second, we were unable to uniformly examine sex differences in these r_g s. Since the prevalence of eating disorders is higher in women than men, and the prevalence of substance use disorders is higher in men than women (American Psychiatric Association, 2013), it will be important to explore possible sex differences in genetic associations as the GWAS data become available. Notably, we previously did not find evidence for sex differences in the r_g between binge eating and problem alcohol use (Munn-Chernoff *et al.*, 2013). Finally, SNP coverage was limited in the earlier GWAS of the BN factor score because that study used older genotyping platforms and imputation panels that included fewer SNPs than current imputation panels. The Eating Disorders and Substance Use Disorders Working Groups of the Psychiatric Genomics Consortium (PGC) are continuously adding samples and releasing data freezes with incrementally larger sample sizes, while collecting information on multiple substances (e.g., opioids). Thus, in coming years, the statistical power is expected to increase for AN (including the *with* and *without* binge-eating subtypes), BN, and BED, as well as AUD, ND, and CUD, from within and outside the PGC. This will allow for a more refined assessment of specific eating disorder symptoms, including binge eating, in relation to substance-use-related phenotypes.

In conclusion, findings from this study suggest that the shared sources of variation in liabilities to eating disorder and substance-use-related phenotypes are not consistent across traits or levels of substance involvement, extending results from twin studies to a genome-wide SNP approach. Despite the typically high co-occurrence of alcohol, tobacco, and cannabis use, and

their genetic overlap (Pasman *et al.*, 2018), the differential patterns seen between the eating disorder- and substance-use-related phenotypes highlight the uniqueness and complexity of their shared etiology. Additional research using contemporary genomic methods such as cross-disorder association studies could identify the specific loci contributing to this comorbidity. Once loci are identified, additional research that combines polygenic risk scores with measured environmental constructs could enhance the prediction, prevention, and treatment of co-occurring eating disorder- and substance-use-related traits.

Acknowledgements

Grant support for individual authors can be found in **Supplementary Table 4**. This study included summary statistics of a genetic study on cannabis use (Pasman et al. [2018] *Nature Neuroscience*). We would like to acknowledge all participating groups of the International Cannabis Consortium, and in particular, the members of the working group including Joelle Pasman, Karin Verweij, Nathan Gillespie, Eske Derks, and Jacqueline Vink. Pasman et al. (2018) included data from the UK Biobank resource under application numbers 9905, 16406, and 25331.

Eating Disorders Working Group of the Psychiatric Genomics Consortium (PGC-ED)

We thank all study volunteers, study coordinators, and research staff who enabled this study. ANGI: The Anorexia Nervosa Genetics Initiative was an initiative of the Klarman Family Foundation. Additional support was offered by the National Institute of Mental Health. We acknowledge support from the North Carolina Translational and Clinical Sciences Institute (NC TraCS) and the Carolina Data Warehouse. PGC: We are deeply indebted to the investigators who comprise the PGC, and to the hundreds of thousands of individuals who have shared their life experiences with PGC investigators and the contributing studies. We are grateful to the Children's Hospital of Philadelphia (CHOP), the Price Foundation Collaborative Group (PFCG), Genetic Consortium for Anorexia Nervosa (GCAN), Wellcome Trust Case-Control Consortium-3 (WTCCC-3), the Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), the QSkin Sun and Health Study, Riksät (Swedish National Quality Register for Eating Disorders), the Stockholm Center for Eating Disorders (SCÄ), LifeGene, the UK Biobank, and all PGC-ED members for their support in providing individual samples used in this

study. We thank SURFsara (<http://www.surf.nl>) for support in using the Lisa Compute Cluster. We thank Max Lam, Institute of Mental Health, Singapore, for Ricopili consultation. This study also represents independent research partly funded by the English National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the English Department of Health and Social Care. High performance computing facilities were funded with capital equipment grants from the GSTT Charity (TR130505) and Maudsley Charity (980). Research reported in this publication was supported by the National Institute of Mental Health of the US National Institutes of Health under Award Number U01MH109514. The content is solely the responsibility of the authors and does not necessarily represent the official views of the U.S. National Institutes of Health.

Substance Use Disorders Working Group of the Psychiatric Genomics Consortium (PGC-SUD)

The PGC-SUD receives support from the National Institute on Drug Abuse and the National Institute of Mental Health via MH109532. We gratefully acknowledge prior support from the National Institute on Alcohol Abuse and Alcoholism. Statistical analyses for the PGC were carried out on the Genetic Cluster Computer (<http://www.geneticcluster.org>) hosted by SURFsara and financially supported by the Netherlands Scientific Organization (NWO 480-05-003) along with a supplement from the Dutch Brain Foundation and the VU University Amsterdam. Cohort specific acknowledgements may be found in Walters et al. (2018) *Nature Neuroscience*.

Competing Financial Interests

The authors report the following potential competing interests. O. Andreassen received a speaker's honorarium from Lundbeck. G. Breen received grant funding and consultancy fees in preclinical genetics from Eli Lilly, consultancy fees from Otsuka, and has received honoraria from Illumina. C. Bulik served on Shire Scientific Advisory Boards; she receives author royalties from Pearson. D. Degortes served as a speaker and on advisory boards, and has received consultancy fees for participation in research from various pharmaceutical industry companies including: AstraZeneca, Boehringer, Bristol Myers Squibb, Eli Lilly, Genesis Pharma, GlaxoSmithKline, Janssen, Lundbeck, Organon, Sanofi, UniPharma, and Wyeth; he has received unrestricted grants from Lilly and AstraZeneca as director of the Sleep Research Unit of Eginition Hospital (National and Kapodistrian University of Athens, Greece). J. Hudson has received grant support from Shire and Sunovion, and has received consulting fees from DiaMentis, Shire, and Sunovion. A. Kaplan is a member of the Shire Canadian BED Advisory Board and was on the steering committee for the Shire B/educated Educational Symposium: June 15-16, 2018. J. Kennedy served as an unpaid member of the scientific advisory board of AssurexHealth Inc. M. Landén declares that, over the past 36 months, he has received lecture honoraria from Lundbeck and served as scientific consultant for EPID Research Oy. No other equity ownership, profit-sharing agreements, royalties, or patent. S. Scherer is a member of the scientific advisory board for Deep Genomics. P. Sullivan is on the Lundbeck advisory committee and is a Lundbeck grant recipient; he has served on the scientific advisory board for Pfizer, has received a consultation fee from Element Genomics, and a speaker reimbursement fee from Roche. J. Treasure has received an honorarium for participation in an EAP meeting and has received royalties from several books from Routledge, Wiley, and Oxford University press. T.

Werge has acted as a lecturer and scientific advisor to H. Lundbeck A/S. L. Bierut, A. Goate, J. Rice, J.-C. Wang, and the spouse of N. Saccone are listed as inventors on Issued US Patent 8080,371, “Markers for Addiction” covering the use of certain SNPs in determining the diagnosis, prognosis, and treatment of addiction. N. Wodarz has received funding from the German Research Foundation (DFG) and Federal Ministry of Education and Research Germany (BMBF); he has received speaker’s honoraria and travel funds from Janssen-Cilag, Mundipharma, and Indivior. He took part in industry-sponsored multicenter randomized trials by D&A Pharma and Lundbeck. M. Ridinger received compensation from Lundbeck Switzerland and Lundbeck institute for advisory boards and expert meetings, and from Lundbeck and Lilly Suisse for workshops and presentations. K. Mann received speaker fees from Janssen Cilag. H. Kranzler has been an advisory board member, consultant, or continuing medical education speaker for Indivior, Lundbeck, and Otsuka. He is a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was sponsored in the past three years by AbbVie, Alkermes, Amygdala Neurosciences, Arbor Pharmaceuticals, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, and Pfizer. H. Kranzler and J. Gelernter are named as inventors on PCT patent application #15/878,640, entitled “Genotype-guided dosing of opioid agonists,” filed 24 January 2018. J. MacKillop is a principal in BEAM Diagnostics, Inc. D.-S. Choi is a scientific advisory member of Peptron Inc. M. Frye has received grant support from Assurex Health, Mayo Foundation, Myriad, NIAAA, National Institute of Mental Health (NIMH), and Pfizer; he has been a consultant for Intra-Cellular Therapies, Inc., Janssen, Mitsubishi Tanabe Pharma Corporation, Myriad, Neuralstem Inc., Otsuka American Pharmaceutical, Sunovion, and Teva Pharmaceuticals. H. de Wit has received support from Insys Therapeutics and Indivior for studies unrelated to this project, and she has consulted for Marinus

and Jazz Pharmaceuticals, also unrelated to this project. T. Wall has previously received funds from ABMRF. J. Nurnberger is an investigator for Janssen. M. Nöthen has received honoraria from the Lundbeck Foundation and the Robert Bosch Stiftung for membership on advisory boards. N. Scherbaum has received honoraria from Abbvie, Sanofi-Aventis, Reckitt Benckiser, Indivior, Lundbeck, and Janssen-Cilag for advisory board membership and the preparation of lectures, manuscripts, and educational materials. Since 2013, N. Scherbaum has also participated in clinical trials financed by Reckitt Benckiser and Indivior. W. Gäbel has received symposia support from Janssen-Cilag GmbH, Neuss, Lilly Deutschland GmbH, Bad Homburg, and Servier, Munich, and is a member of the Faculty of the Lundbeck International Neuroscience Foundation (LINF), Denmark. J. Kaprio has provided consultations on nicotine dependence for Pfizer (Finland) 2012–2015. In the past three years, L. Degenhardt has received investigator-initiated untied educational grants for studies of opioid medications in Australia from Indivior, Mundipharma, and Seqirus. B. Neale is a member of the scientific advisory board for Deep Genomics and has consulted for Camp4 Therapeutics Corporation, Merck & Co., and Avanir Pharmaceuticals, Inc. A. Agrawal previously received peer-reviewed funding and travel reimbursement from ABMRF for unrelated research. All other authors have no conflicts of interest, relevant to the contents of this paper, to disclose.

Authors Contribution

M. Munn-Chernoff, C. Bulik, and A. Agrawal were responsible for the study concept and design. M. Munn-Chernoff, E.C. Johnson, and Y.-L. Duan performed the statistical analyses, and J. Coleman, R. Walters, and Z. Yilmaz assisted with the data analysis. M. Munn-Chernoff, E.C. Johnson, Y.L. Duan, J. Coleman, L. Thornton, R. Walters, Z. Yilmaz, J. Baker, C. Hübel, J. Kaprio, H. Edenberg, C. Bulik, and A. Agrawal assisted with interpretation of findings. H. Kranzler, J. Gelernter, and H. Zhou facilitated access to and interpretation of the Million Veteran Program summary statistics for AUD. M. Munn-Chernoff, E.C. Johnson, L. Thornton, C. Bulik, and A. Agrawal drafted the manuscript. All remaining authors provided data for this study and consulted on the analytic plan. All authors critically reviewed the content and approved the final version for publication.

References

- 1000 Genomes Project Consortium, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL, McCarthy S, McVean GA, Abecasis GR (2015). A global reference for human genetic variation. *Nature* 526:68-74.
- Andries A, Frystyk J, Flyvbjerg A, Stoving RK (2014). Dronabinol in severe, enduring anorexia nervosa: A randomized controlled trial. *Int J Eat Disord* 47:18-23.
- American Psychiatric Association (2013). *Diagnostic and statistical manual of mental disorders* (5th ed.). Arlington, VA: Author.
- Anzengruber D, Klump KL, Thornton L, Brandt H, Crawford S, Fichter MM, Halmi KA, Johnson C, Kaplan AS, LaVia M, Mitchell J, Strober M, Woodside DB, Rotondo A, Berrettini WH, Kaye WH, Bulik CM (2006). Smoking in eating disorders. *Eat Behav* 7:291-299.
- Avraham Y, Paturski I, Magen I, Vorobiev L, Berry EM (2017). 2-Arachidonoylglycerol as a possible treatment for anorexia nervosa in animal model in mice. *Brain Res* 1670:185-190.
- Baker JH, Mazzeo SE, Kendler KS (2007). Association between broadly defined bulimia nervosa and drug use disorders: Common genetic and environmental influences. *Int J Eat Disord* 40:673-678.

Baker JH, Mitchell KS, Neale MC, Kendler KS (2010). Eating disorder symptomatology and substance use disorders: Prevalence and shared risk in a population based twin sample. *Int J Eat Disord* 43:648-658.

Baker JH, Munn-Chernoff MA, Lichtenstein P, Larsson H, Maes H, Kendler KS (2017). Shared familial risk between bulimic symptoms and alcohol involvement during adolescence. *J Abnorm Psychol* 126:506-518.

Benjamini Y and Hochberg Y (1995). Controlling the false discovery rate: A practical and powerful approach to multiple testing. *J Royal Statist Soc, Series B*, 57:449-518.

Bulik-Sullivan B, Finucane HK, Anttila V, Gusev A, Day FR, Loh PR, ReproGen Consortium, Psychiatric Genomics Consortium, Genetic Consortium for Anorexia Nervosa of the Wellcome Trust Case Control Consortium 3, Duncan L, Perry JR, Patterson N, Robinson EB, Daly MJ, Price AL, Neale BM (2015a). An atlas of genetic correlations across human diseases and traits. *Nat Genet* 47:1236-1241.

Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Schizophrenia Working Group of the Psychiatric Genomics Consortium, Patterson N, Daly MJ, Price AL, Neale BM (2015b). LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet* 47:291-295.

Center on Addiction and Substance Abuse (2003). Food for thought: Substance abuse and eating disorders. Columbia University (ed). The National Center on Addiction and Substance Abuse at Columbia University: New York, NY. pp 1-83.

Demontis D, Rajagopal VM, Thorgeirsson TE, Als TD, Grove J, Leppala K, Gudbjartsson DF, Pallesen J, Hjorthoj C, Reginsson GW, Tyrfingsson T, Runarsdottir V, Qvist P, Christensen JH, Bybjerg-Grauholm J, Baekvad-Hansen M, Huckins LM, Stahl EA, Timmermann A, Agerbo E, Hougaard DM, Werge T, Mors O, Mortensen PB, Nordentoft M, Daly MJ, Stefansson H, Stefansson K, Nyegaard M, Borglum AD (2019). Genome-wide association study implicates *CHRNA2* in cannabis use disorder. *Nat Neurosci* 22:1066-1074.

Di Marzo V and Matias I (2005). Endocannabinoid control of food intake and energy balance. *Nat Neurosci* 8:585-589.

Duncan AE, Neuman RJ, Kramer JR, Kuperman S, Hesselbrock VM, Bucholz KK (2006). Lifetime psychiatric comorbidity of alcohol dependence and bulimia nervosa in women. *Drug Alcohol Depend* 84:122-132.

Duncan L, Yilmaz Z, Gaspar H, Walters R, Goldstein J, Anttila V, Bulik-Sullivan B, Ripke S, Eating Disorders Working Group of the Psychiatric Genomics Consortium, Thornton L, Hinney A, Daly M, Sullivan PF, Zeggini E, Breen G, Bulik CM (2017). Significant locus and metabolic genetic correlations revealed in genome-wide association study of anorexia nervosa. *Am J Psychiatry* 174:850-858.

Fairburn CG and Cooper Z (1993). The Eating Disorder Examination. In: *Binge Eating: Nature, Assessment and Treatment*. Fairburn CG, Wilson GT (eds). Guilford Press: New York. pp. 317-359.

Filozof C, Fernandez Pinilla MC, Fernandez-Cruz A (2004). Smoking cessation and weight gain. *Obes Rev* 5:95-103.

Franko DL, Keshaviah A, Eddy KT, Krishna M, Davis MC, Keel PK, Herzog DB (2013). A longitudinal investigation of mortality in anorexia nervosa and bulimia nervosa. *Am J Psychiatry* 170:917-925.

Gadalla T and Piran N (2007). Co-occurrence of eating disorders and alcohol use disorders in women: A meta analysis. *Arch Womens Ment Health* 10:133-140.

Goodarzi MO (2018). Genetics of obesity: What genetic association studies have taught us about the biology of obesity and its complications. *Lancet Diabetes Endocrinol* 6:223-236.

Gregorowski C, Seedat S, Jordaan GP (2013). A clinical approach to the assessment and management of co-morbid eating disorders and substance use disorders. *BMC Psychiatry* 13, 289.

Hancock DB, Guo Y, Reginsson GW, Gaddis NC, Lutz SM, Sherva R, Loukola A, Minica CC, Markunas CA, Han Y, Young KA, Gudbjartsson DF, Gu F, McNeil DW, Qaiser B, Glasheen C, Olson S, Landi MT, Madden PAF, Farrer LA, Vink J, Saccone NL, Neale MC, Kranzler HR, McKay J, Hung RJ, Amos CI, Marazita ML, Boomsma DI, Baker TB, Gelernter J, Kaprio J, Caporaso NE, Thorgeirsson TE, Hokanson JE, Bierut LJ, Stefansson K, Johnson EO (2017). Genome-wide association study across European and African American ancestries identifies a SNP in DNMT3B contributing to nicotine dependence. *Mol Psychiatry* 23:1-9.

Heath AC, Bucholz KK, Madden PA, Dinwiddie SH, Slutske WS, Bierut LJ, Statham DJ, Dunne MP, Whitfield JB, Martin NG (1997). Genetic and environmental contributions to alcohol dependence risk in a national twin sample: Consistency of findings in women and men. *Psychol Med* 27:1381-1396.

Jonas JM and Gold MS (1988). The use of opiate antagonists in treating bulimia: A study of low-dose versus high-dose naltrexone. *Psychiatry Res* 24:195-199.

Kaye WH, Wierenga CE, Bailer UF, Simmons AN, Wagner A, Bischoff-Grethe A (2013). Does a shared neurobiology for foods and drugs of abuse contribute to extremes of food ingestion in anorexia and bulimia nervosa? *Biol Psychiatry* 73, 836-842.

Kranzler HR and Soyka M (2018). Diagnosis and pharmacotherapy of alcohol use disorder: A review. *JAMA* 320:815-824.

Kranzler HR, Zhou H, Kember RL, Vickers Smith R, Justice AC, Damrauer S, Tsao PS, Klarin D, Baras A, Reid J, Overton J, Rader DJ, Cheng Z, Tate JP, Becker WC, Concato J, Xu K, Polimanti R, Zhao H, Gelernter J (2019). Genome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations. *Nat Commun* 10:1499.

Krug I, Treasure J, Anderluh M, Bellodi L, Cellini E, di BM, Granero R, Karwautz A, Nacmias B, Penelo E, Ricca V, Sorbi S, Tchanturia K, Wagner G, Collier D, Fernandez-Aranda F (2008). Present and lifetime comorbidity of tobacco, alcohol and drug use in eating disorders: A European multicenter study. *Drug Alcohol Depend* 97:169-179.

Liu M, Jiang Y, Wedow R, Li Y, Brazel DM, Chen F, Datta G, Davila-Velderrain J, McGuire D, Tian C, Zhan X, 23andMe Research Team, HUNT All-In Psychiatry, Choquet H, Docherty AR, Faul JD, Foerster JR, Fritsche LG, Gabrielsen ME, Gordon SD, Haessler J, Hottenga JJ, Huang H, Jang SK, Jansen PR, Ling Y, Magi R, Matoba N, McMahon G, Mulas A, Orru V, Palviainen T, Pandit A, Reginsson GW, Skogholt AH, Smith JA, Taylor AE, Turman C, Willemsen G, Young H, Young KA, Zajac GJM, Zhao W, Zhou W, Bjornsdottir G, Boardman JD, Boehnke M, Boomsma DI, Chen C, Cucca F, Davies GE, Eaton CB, Ehringer MA, Esko T, Fiorillo E, Gillespie NA, Gudbjartsson DF, Haller T, Harris KM, Heath AC, Hewitt JK, Hickie IB, Hokanson JE, Hopfer CJ, Hunter DJ, Iacono WG, Johnson EO, Kamatani Y, Kardina SLR, Keller MC, Kellis M, Kooperberg C, Kraft P, Krauter KS, Laakso M, Lind PA, Loukola A, Lutz SM, Madden PAF, Martin NG, McGue M, McQueen MB, Medland SE, Metspalu A, Mohlke KL, Nielsen JB, Okada Y, Peters U, Polderman TJC, Posthuma D, Reiner AP, Rice JP, Rimm E,

Rose RJ, Runarsdottir V, Stallings MC, Stancakova A, Stefansson H, Thai KK, Tindle HA, Tyrfingsson T, Wall TL, Weir DR, Weisner C, Whitfield JB, Winsvold BS, Yin J, Zuccolo L, Bierut LJ, Hveem K, Lee JJ, Munafo MR, Saccone NL, Willer CJ, Cornelis MC, David SP, Hinds DA, Jorgenson E, Kaprio J, Stitzel JA, Stefansson K, Thorgeirsson TE, Abecasis G, Liu DJ, Vrieze S (2019). Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use. *Nat Genet* 51:237-244.

Monteleone P and Maj M (2013). Dysfunctions of leptin, ghrelin, BDNF and endocannabinoids in eating disorders: Beyond the homeostatic control of food intake. *Psychoneuroendocrinology* 38, 312-330.

Munn-Chernoff MA and Baker JH (2016). A primer on the genetics of comorbid eating disorders and substance use disorders. *Eur Eat Disord Rev* 24:91-100.

Munn-Chernoff MA, Duncan AE, Grant JD, Wade TD, Agrawal A, Bucholz KK, Madden PAF, Martin NG, Heath AC (2013). A twin study of the association between alcohol dependence, binge eating, and compensatory behaviors. *J Stud Alcohol Drugs* 74, 664-673.

Munn-Chernoff MA, Grant JD, Agrawal A, Sartor CE, Werner KB, Bucholz KK, Madden PA, Heath AC, Duncan AE (2015). Genetic overlap between alcohol use disorder and bulimic behaviors in European American and African American women. *Drug Alcohol Depend* 153:335-40.

Pasman JA, Verweij KJH, Gerring Z, Stringer S, Sanchez-Roige S, Treur JL, Abdellaoui A, Nivard MG, Baselmans BML, Ong JS, Ip HF, van der Zee MD, Bartels M, Day FR, Fontanillas P, Elson SL, 23andMe Research Team, de Wit H, Davis LK, MacKillop J, Substance Use Disorders Working Group of the Psychiatric Genomics Consortium, International Cannabis Consortium, Derringer JL, Branje SJT, Hartman CA, Heath AC, van Lier PAC, Madden PAF, Magi R, Meeus W, Montgomery GW, Oldehinkel AJ, Pausova Z, Ramos-Quiroga JA, Paus T, Ribases M, Kaprio J, Boks MPM, Bell JT, Spector TD, Gelernter J, Boomsma DI, Martin NG, MacGregor S, Perry JRB, Palmer AA, Posthuma D, Munafò MR, Gillespie NA, Derks EM, Vink JM (2018). GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal influence of schizophrenia. *Nat Neurosci* 21:1161-1170.

Reuter SE and Martin JH (2016). Pharmacokinetics of cannabis in cancer cachexia-anorexia syndrome. *Clin Pharmacokinet* 55:807-812.

Rhee SH, Hewitt JK, Young SE, Corley RP, Crowley TJ, Stallings MC (2003). Genetic and environmental influences on substance initiation, use, and problem use in adolescents. *Arch Gen Psychiatry* 60:1256-1264.

Root TL, Pisetsky EM, Thornton L, Lichtenstein P, Pedersen NL, Bulik CM (2010). Patterns of co-morbidity of eating disorders and substance use in Swedish females. *Psychol Med* 40:105-115.

Slane JD, Burt SA, Klump KL (2012). Bulimic behaviors and alcohol use: Shared genetic influences. *Behav Genet* 42:603-613.

Smith GD and Ebrahim S (2003). 'Mendelian randomization': Can genetic epidemiology contribute to understanding environmental determinants of disease? *Int J Epidemiol* 32:1-22.

Solmi M, Veronese N, Sergi G, Luchini C, Favaro A, Santonastaso P, Vancampfort D, Correll CU, Ussher M, Thapa-Chhetri N, Fornaro M, Stubbs B (2016). The association between smoking prevalence and eating disorders: A systematic review and meta-analysis. *Addiction* 111, 1914-1922.

Stancil SL, Adelman W, Dietz A, Abdel-Rahman S (in press). Naltrexone reduces binge eating and purging in adolescents in an eating disorder program. *J Child Adolesc Psychopharmacol*. doi: 10.1089/cap.2019.0056.

Trace SE, Thornton LM, Baker JH, Root TL, Janson LE, Lichtenstein P, Pedersen NL, Bulik CM (2013). A behavioral-genetic investigation of bulimia nervosa and its relationship with alcohol use disorder. *Psychiatry Res* 208:232-237.

True WR, Heath AC, Scherrer JF, Waterman B, Goldberg J, Lin N, Eisen SA, Lyons MJ, Tsuang MT (1997). Genetic and environmental contributions to smoking. *Addiction* 92:1277-1287.

van den Bree MB, Johnson EO, Neale MC, Pickens RW (1998). Genetic and environmental influences on drug use and abuse/dependence in male and female twins. *Drug Alcohol Depend* 52:231-241.

Volkow ND, Hampson AJ, Baler RD (2017). Don't worry, be happy: Endocannabinoids and cannabis at the intersection of stress and reward. *Annu Rev Pharmacol Toxicol* 57:285-308.

Volkow ND, Wang GJ, Tomasi D, Baler RD (2013). The addictive dimensionality of obesity. *Biol Psychiatry* 73:811-818.

Wade TD, Gordon S, Medland S, Bulik CM, Heath AC, Montgomery GW, Martin NG (2013). Genetic variants associated with disordered eating. *Int J Eat Disord* 46:594-608.

Walters RK, Polimanti R, Johnson EC, McClintick JN, Adams MJ, Adkins AE, Aliev F, Bacanu SA, Batzler A, Bertelsen S, Biernacka JM, Bigdeli TB, Chen LS, Clarke TK, Chou YL, Degenhardt F, Docherty AR, Edwards AC, Fontanillas P, Foo JC, Fox L, Frank J, Giegling I, Gordon S, Hack LM, Hartmann AM, Hartz SM, Heilmann-Heimbach S, Herms S, Hodgkinson C, Hoffmann P, Jan Hottenga J, Kennedy MA, Alanne-Kinnunen M, Konte B, Lahti J, Lahti-Pulkkinen M, Lai D, Ligthart L, Loukola A, Maher BS, Mbarek H, McIntosh AM, McQueen MB, Meyers JL, Milaneschi Y, Palviainen T, Pearson JF, Peterson RE, Ripatti S, Ryu E, Saccone NL, Salvatore JE, Sanchez-Roige S, Schwandt M, Sherva R, Streit F, Strohmaier J, Thomas N, Wang JC, Webb BT, Wedow R, Wetherill L, Wills AG, 23andMe Research Team, Boardman JD, Chen D, Choi DS, Copeland WE, Culverhouse RC, Dahmen N, Degenhardt L,

Domingue BW, Elson SL, Frye MA, Gabel W, Hayward C, Ising M, Keyes M, Kiefer F, Kramer J, Kuperman S, Lucae S, Lynskey MT, Maier W, Mann K, Mannisto S, Muller-Myhsok B, Murray AD, Nurnberger JI, Palotie A, Preuss U, Raikkonen K, Reynolds MD, Ridinger M, Scherbaum N, Schuckit MA, Soyka M, Treutlein J, Witt S, Wodarz N, Zill P, Adkins DE, Boden JM, Boomsma DI, Bierut LJ, Brown SA, Bucholz KK, Cichon S, Costello EJ, de Wit H, Diazgranados N, Dick DM, Eriksson JG, Farrer LA, Foroud TM, Gillespie NA, Goate AM, Goldman D, Grucza RA, Hancock DB, Harris KM, Heath AC, Hesselbrock V, Hewitt JK, Hopfer CJ, Horwood J, Iacono W, Johnson EO, Kaprio JA, Karpyak VM, Kendler KS, Kranzler HR, Krauter K, Lichtenstein P, Lind PA, McGue M, MacKillop J, Madden PAF, Maes HH, Magnusson P, Martin NG, Medland SE, Montgomery GW, Nelson EC, Nothen MM, Palmer AA, Pedersen NL, Penninx B, Porjesz B, Rice JP, Rietschel M, Riley BP, Rose R, Rujescu D, Shen PH, Silberg J, Stallings MC, Tarter RE, Vanyukov MM, Vrieze S, Wall TL, Whitfield JB, Zhao H, Neale BM, Gelernter J, Edenberg HJ, Agrawal A (2018). Transancestral GWAS of alcohol dependence reveals common genetic underpinnings with psychiatric disorders. *Nat Neurosci* 21:1656-1669.

Watson HJ, Yilmaz Z, Thornton LM, Hubel C, Coleman JRI, Gaspar HA, Bryois J, Hinney A, Leppa VM, Mattheisen M, Medland SE, Ripke S, Yao S, Giusti-Rodriguez P, Anorexia Nervosa Genetics Initiative, Hanscombe KB, Purves KL, Eating Disorders Working Group of the Psychiatric Genomics Consortium, Adan RAH, Alfredsson L, Ando T, Andreassen OA, Baker JH, Berrettini WH, Boehm I, Boni C, Perica VB, Buehren K, Burghardt R, Cassina M, Cichon S, Clementi M, Cone RD, Courtet P, Crow S, Crowley JJ, Danner UN, Davis OSP, de Zwaan M, Dedoussis G, Degortes D, DeSocio JE, Dick DM, Dikeos D, Dina C, Dmitrzak-Weglarz M,

Docampo E, Duncan LE, Egberts K, Ehrlich S, Escaramis G, Esko T, Estivill X, Farmer A, Favaro A, Fernandez-Aranda F, Fichter MM, Fischer K, Focker M, Foretova L, Forstner AJ, Forzan M, Franklin CS, Gallinger S, Giegling I, Giuranna J, Gonidakis F, Gorwood P, Mayora MG, Guillaume S, Guo Y, Hakonarson H, Hatzikotoulas K, Hauser J, Hebebrand J, Helder SG, Herms S, Herpertz-Dahlmann B, Herzog W, Huckins LM, Hudson JI, Imgart H, Inoko H, Janout V, Jimenez-Murcia S, Julia A, Kalsi G, Kaminska D, Kaprio J, Karhunen L, Karwautz A, Kas MJH, Kennedy JL, Keski-Rahkonen A, Kiezebrink K, Kim YR, Klareskog L, Klump KL, Knudsen GPS, La Via MC, Le Hellard S, Levitan RD, Li D, Lilenfeld L, Lin BD, Lissowska J, Luykx J, Magistretti PJ, Maj M, Mannik K, Marsal S, Marshall CR, Mattingsdal M, McDevitt S, McGuffin P, Metspalu A, Meulenbelt I, Micali N, Mitchell K, Monteleone AM, Monteleone P, Munn-Chernoff MA, Nacmias B, Navratilova M, Ntalla I, O'Toole JK, Ophoff RA, Padyukov L, Palotie A, Pantel J, Papezova H, Pinto D, Rabionet R, Raevuori A, Ramoz N, Reichborn-Kjennerud T, Ricca V, Ripatti S, Ritschel F, Roberts M, Rotondo A, Rujescu D, Rybakowski F, Santonastaso P, Scherag A, Scherer SW, Schmidt U, Schork NJ, Schosser A, Seitz J, Slachtova L, Slagboom PE, Slof-Op 't Landt MCT, Slopian A, Sorbi S, Swiatkowska B, Szatkiewicz JP, Tachmazidou I, Tenconi E, Tortorella A, Tozzi F, Treasure J, Tsitsika A, Tyszkiewicz-Nwafor M, Tziouvas K, van Elburg AA, van Furth EF, Wagner G, Walton E, Widen E, Zeggini E, Zerwas S, Zipfel S, Bergen AW, Boden JM, Brandt H, Crawford S, Halmi KA, Horwood LJ, Johnson C, Kaplan AS, Kaye WH, Mitchell JE, Olsen CM, Pearson JF, Pedersen NL, Strober M, Werge T, Whiteman DC, Woodside DB, Stuber GD, Gordon S, Grove J, Henders AK, Jureus A, Kirk KM, Larsen JT, Parker R, Petersen L, Jordan J, Kennedy M, Montgomery GW, Wade TD, Birgegard A, Lichtenstein P, Noring C, Landen M, Martin NG, Mortensen PB, Sullivan PF,

Breen G, Bulik CM (2019). Genome-wide association study identifies eight risk loci and implicates metabo-psychiatric origins for anorexia nervosa. *Nat Genet* 51:1207-1214.

White MA (2011). Smoking for weight control and its associations with eating disorder symptomatology. *Compr Psychiatry* 53:403-407.

Wiederman MW and Pryor T (1996). Substance use among women with eating disorders. *Int J Eat Disord* 20:163-168.

Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, Adams MJ, Agerbo E, Air TM, Andlauer TMF, Bacanu SA, Baekvad-Hansen M, Beekman AFT, Bigdeli TB, Binder EB, Blackwood DRH, Bryois J, Buttenschon HN, Bybjerg-Grauholm J, Cai N, Castelao E, Christensen JH, Clarke TK, Coleman JIR, Colodro-Conde L, Couvy-Duchesne B, Craddock N, Crawford GE, Crowley CA, Dashti HS, Davies G, Deary IJ, Degenhardt F, Derks EM, Direk N, Dolan CV, Dunn EC, Eley TC, Eriksson N, Escott-Price V, Kiadeh FHF, Finucane HK, Forstner AJ, Frank J, Gaspar HA, Gill M, Giusti-Rodriguez P, Goes FS, Gordon SD, Grove J, Hall LS, Hannon E, Hansen CS, Hansen TF, Herms S, Hickie IB, Hoffmann P, Homuth G, Horn C, Hottenga JJ, Hougaard DM, Hu M, Hyde CL, Ising M, Jansen R, Jin F, Jorgenson E, Knowles JA, Kohane IS, Kraft J, Kretschmar WW, Krogh J, Kutalik Z, Lane JM, Li Y, Li Y, Lind PA, Liu X, Lu L, MacIntyre DJ, MacKinnon DF, Maier RM, Maier W, Marchini J, Mbarek H, McGrath P, McGuffin P, Medland SE, Mehta D, Middeldorp CM, Mihailov E, Milaneschi Y, Milani L, Mill J, Mondimore FM, Montgomery GW, Mostafavi S, Mullins N, Nauck M, Ng B, Nivard MG, Nyholt DR, O'Reilly PF, Oskarsson H, Owen MJ, Painter JN, Pedersen CB,

Pedersen MG, Peterson RE, Pettersson E, Peyrot WJ, Pistis G, Posthuma D, Purcell SM, Quiroz JA, Qvist P, Rice JP, Riley BP, Rivera M, Saeed Mirza S, Saxena R, Schoevers R, Schulte EC, Shen L, Shi J, Shyn SI, Sigurdsson E, Sinnamoni GBC, Smit JH, Smith DJ, Stefansson H, Steinberg S, Stockmeier CA, Streit F, Strohmaier J, Tansey KE, Teismann H, Teumer A, Thompson W, Thomson PA, Thorgeirsson TE, Tian C, Traylor M, Treutlein J, Trubetskoy V, Uitterlinden AG, Umbricht D, Van der Auwera S, van Hemert AM, Viktorin A, Visscher PM, Wang Y, Webb BT, Weinsheimer SM, Wellmann J, Willemsen G, Witt SH, Wu Y, Xi HS, Yang J, Zhang F; eQTLGen; 23andMe, Arolt V, Baune BT, Berger K, Boomsma DI, Cichon S, Dannlowski U, de Geus ECJ, DePaulo JR, Domenici E, Domschke K, Esko T, Grabe HJ, Hamilton SP, Hayward C, Heath AC, Hinds DA, Kendler KS, Kloiber S, Lewis G, Li QS, Lucae S, Madden PFA, Magnusson PK, Martin NG, McIntosh AM, Metspalu A, Mors O, Mortensen PB, Muller-Myhsok B, Nordentoft M, Nothen MM, O'Donovan MC, Paciga SA, Pedersen NL, Penninx B, Perlis RH, Porteous DJ, Potash JB, Preisig M, Rietschel M, Schaefer C, Schulze TG, Smoller JW, Stefansson K, Tiemeier H, Uher R, Volzke H, Weissman MM, Werge T, Winslow AR, Lewis CM, Levinson DF, Breen G, Borglum AD, Sullivan PF, & Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium (2018). Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. *Nat Genet* 50:668-681.

Yengo L, Yang J, Visscher PM (2018). Expectation of the intercept from bivariate LD score regression in the presence of population stratification. *bioRxiv*, <https://doi.org/10.1101/310565>.

Zhu Z, Zheng Z, Zhang F, Wu Y, Trzaskowski M, Maier R, Robinson MR, McGrath JJ, Visscher PM, Wray NR, Yang J (2018). Causal associations between risk factors and common diseases inferred from GWAS summary data. *Nat Commun* 9, 224.

Table 1. Eating disorder-related phenotype descriptions.

Phenotype	Definitions
Anorexia nervosa (AN) ^a	Diagnostic criteria included: <ol style="list-style-type: none"> 1. BMI less than minimally expected 2. Intense fear of gaining weight 3. Weight or shape disturbance, undue influence of weight or shape, or denial of the seriousness of the disorder
AN <i>with</i> binge-eating ^b	Individuals with AN who also engaged in binge eating episodes, defined as eating a large amount of food in a short period of time while having a sense of loss of control over the eating episode. The binge eating episodes must have occurred at least twice a week for three months.
AN <i>without</i> binge-eating ^b	Individuals with AN who did not engage in binge eating episodes.
Bulimia nervosa (BN) ^c factor	Derived from a factor analysis that included the following items: <ol style="list-style-type: none"> 1. Reporting self-induced vomiting to control body weight 2. Reporting suffering from or being treated for binge eating 3. Reporting suffering from or being treated for bulimia

Note: ^aA fourth diagnostic criterion for AN includes amenorrhea. However, amenorrhea was excluded as a required criterion for cases in the Psychiatric Genomics Consortium datasets since it is no longer a diagnostic criterion in the DSM-5. ^bThe DSM and ICD include two subtypes of anorexia nervosa (AN)—a binge-eating/purging subtype and a restricting subtype. Although it would have been ideal to examine differences between the AN binge-eating/purging subtype and AN restricting subtype, this was not possible with current Psychiatric Genomics Consortium data. However, there was sufficient information about presence or absence of binge eating, which resulted in creating the AN *with* binge-eating and AN *without* binge-eating subtypes. ^cBulimia nervosa is defined as: 1) recurrent episodes of binge eating; 2) recurrent inappropriate compensatory behaviors (e.g., self-induced vomiting, laxative use) to prevent weight gain; 3) the binge eating and inappropriate compensatory behaviors occurring an average of twice a week for three months; 4) having undue influence of body weight and shape; and 5) disturbance not occurring during AN.

Table 2. Details of samples included in analyses.

Study	Sample/Consortium	Phenotype(s)	Definition	Sample Size (cases / controls if binary)	Number of SNPs in summary statistics file
<i>Eating Disorder Phenotype</i>					
Watson et al. (2019)	PGC-ED	1. Anorexia nervosa	DSM-III-R, DSM-IV, ICD-8,	16,992 / 55,525	8,219,102
		2. Anorexia nervosa <i>with</i> binge-eating	ICD-9, ICD-10, or self-reported anorexia nervosa	2,381 / 10,249	8,982,440
		3. Anorexia nervosa <i>without</i> binge-eating		2,262 / 10,254	8,671,192
Wade et al. (2013)	Australian Twin Registry	Bulimia nervosa factor	Eating Disorder Examination	151 / 2,291	6,150,213
<i>Substance Use-Related Phenotype</i>					
Kranzler et al. (2019)	MVP	Alcohol use disorder	ICD-9 or ICD-10	34,658 / 167,346	6,895,251
Walters et al. (2018)	PGC-SUD	Alcohol dependence	DSM-IV	8,485 / 20,272	9,271,145
Liu et al. (2019)	GSCAN	1. Drinks per week*	Average number of drinks each week	537,349	11,916,707
		2. Smoking initiation	Ever vs. never regular smoker	311,629 / 321,173	11,733,344
		3. Current smoking ^a	Current vs. former smokers	92,573 / 220,248	12,197,133

Table 2 (cont). Details of samples included in analyses.

Study	Sample/Consortium	Phenotype(s)	Definition	Sample Size (cases / controls if binary)	Number of SNPs in summary statistics file
		4. Cigarettes per day*	Average number of cigarettes smoked per day	263,954	12,003,613
Hancock et al. (2017)	14 consortia	Nicotine dependence**	Mild (FTND score 0-3), Moderate (FTND score 4-6), or Severe (FTND score 7-10)	14,184 (Mild) 9,206 (Moderate) 5,287 (Severe)	10,622,668
Pasman et al. (2018)	ICC UK Biobank	Cannabis initiation	Lifetime cannabis use	43,380 / 118,702	11,733,371
Demontis et al. (2019)	iPSYCH	Cannabis use disorder	ICD-10	2,387 / 48,985	8,969,939

Note: SNPs=single nucleotide polymorphisms; PGC-ED=Eating Disorders Working Group of the Psychiatric Genomics Consortium; DSM=Diagnostic and Statistical Manual; ICD=International Classification of Diseases; PGC-SUD=Substance Use Disorders Working Group of the Psychiatric Genomics Consortium; MVP=Million Veteran Program; GSCAN=GWAS & Sequencing Consortium of Alcohol and Nicotine use; FTND=Fagerstr m Test of Nicotine Dependence; ICC=International Cannabis Consortium; iPSYCH=Lundbeck Foundation Initiative for Integrative Psychiatric Research. *Treated as a continuous phenotype. **Treated as an

ordinal phenotype. ^aIn Lui et al. (2019), the phenotype is labeled as “smoking cessation”. It was renamed as “current smoking” to reflect the coding scheme and for ease in comparing across all smoking phenotypes.

Figure 1. Genetic correlations between eating disorder subtypes and substance-use-related

phenotypes. AN=anorexia nervosa; ANBE=anorexia nervosa *with* binge-eating;

ANnoBE=anorexia nervosa *without* binge-eating; BNFac=bulimia nervosa factor score;

DPW=drinks per week; AUD=alcohol use disorder; SmkInit=smoking initiation;

CurrSmk=current smoking; CPD=cigarettes per day; ND=nicotine dependence;

CanInit=cannabis initiation; CUD=cannabis use disorder. # indicates known or potential sample

overlap with UK Biobank; & indicates known sample overlap with iPSYCH. Bolded and *

values denote significant genetic correlations after correcting for multiple comparisons using

False Discovery Rate (n tests=66; $q<0.05$).

